

# UCLA

## UCLA Previously Published Works

### Title

Partial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-bet+ B cells

### Permalink

<https://escholarship.org/uc/item/0pk2d3d3>

### Journal

Nature Immunology, 23(8)

### ISSN

1529-2908

### Authors

Csomos, Krisztian

Ujhazi, Boglarka

Blazso, Peter

et al.

### Publication Date

2022-08-01

### DOI

10.1038/s41590-022-01271-6

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



OPEN

# Partial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-bet<sup>+</sup> B cells

Krisztian Csomos<sup>1</sup>✉, Boglarka Ujhazi<sup>1</sup>, Peter Blazso<sup>1,2</sup>, Jose L. Herrera<sup>3,4</sup>, Christopher M. Tipton<sup>5</sup>, Tomoki Kawai<sup>6</sup>, Sumai Gordon<sup>1</sup>, Maryssa Ellison<sup>1</sup>, Kevin Wu<sup>1</sup>, Matthew Stowell<sup>1</sup>, Lauren Haynes<sup>1</sup>, Rachel Cruz<sup>1</sup>, Bence Zakota<sup>1</sup>, Johnny Nguyen<sup>7</sup>, Michelle Altrich<sup>8</sup>, Christoph B. Geier<sup>9</sup>, Svetlana Sharapova<sup>10</sup>, Joseph F. Dasso<sup>1</sup>, Jennifer W. Leiding<sup>1</sup>, Grace Smith<sup>11</sup>, Waleed Al-Herz<sup>12</sup>, Mayra de Barros Dorna<sup>13</sup>, Olajumoke Fadugba<sup>14</sup>, Eva Fronkova<sup>15</sup>, Veronika Kanderova<sup>15</sup>, Michael Svaton<sup>15</sup>, Sarah E. Henrickson<sup>16,17</sup>, Joseph D. Hernandez<sup>18</sup>, Taco Kuijpers<sup>19</sup>, Snezhina Mihailova Kandilarova<sup>20</sup>, Elizaveta Naumova<sup>20</sup>, Tomas Milota<sup>21</sup>, Anna Sediva<sup>21</sup>, Despina Moshous<sup>22,23,24</sup>, Benedicte Neven<sup>22,23,25</sup>, Tara Saco<sup>26</sup>, Ravishankar Sargur<sup>27</sup>, Sinisa Savic<sup>28,29</sup>, John Sleasman<sup>30</sup>, Gauri Sunkersett<sup>31</sup>, Brant R. Ward<sup>32</sup>, Masanobu Komatsu<sup>3,4</sup>, Stefania Pittaluga<sup>11</sup>, Attila Kumanovics<sup>33</sup>, Manish J. Butte<sup>34</sup>, Michael P. Cancro<sup>35</sup>, Shiv Pillai<sup>36</sup>, Eric Meffre<sup>37,38</sup>, Luigi D. Notarangelo<sup>6</sup> and Jan E. Walter<sup>1,39</sup>✉

**The recombination-activating genes (RAG) 1 and 2 are indispensable for diversifying the primary B cell receptor repertoire and pruning self-reactive clones via receptor editing in the bone marrow; however, the impact of RAG1/RAG2 on peripheral tolerance is unknown. Partial RAG deficiency (pRD) manifesting with late-onset immune dysregulation represents an ‘experiment of nature’ to explore this conundrum. By studying B cell development and subset-specific repertoires in pRD, we demonstrate that reduced RAG activity impinges on peripheral tolerance through the generation of a restricted primary B cell repertoire, persistent antigenic stimulation and an inflammatory milieu with elevated B cell-activating factor. This unique environment gradually provokes profound B cell dysregulation with widespread activation, remarkable extrafollicular maturation and persistence, expansion and somatic diversification of self-reactive clones. Through the model of pRD, we reveal a RAG-dependent ‘domino effect’ that impacts stringency of tolerance and B cell fate in the periphery.**

**R**AG 1 and 2 orchestrate the process of V(D)J recombination during the early stage of B cell development in the bone marrow (BM)<sup>1</sup>. In humans, pathogenic biallelic hypomorphic RAG variants decrease but do not fully abrogate the recombinase activity of the RAG proteins<sup>2,3</sup> and result in restricted T cell antigen receptor (TCR)/B cell antigen receptor (BCR) repertoires and low-to-normal peripheral blood lymphocytes with variable autoantibody profiles<sup>4,5</sup>.

As the diverse pre-immune BCR repertoire forms, self-reactive, potentially harmful clones are also naturally generated<sup>6</sup>. To maintain self-tolerance, three central tolerance mechanisms (receptor editing, deletion and anergy) efficiently purge the majority of nascent self-reactive B cell clones<sup>6,7</sup>. As the RAG1/RAG2 complex plays a direct role in receptor editing<sup>8</sup>, pRD could lower its efficiency allowing the inclusion of self-reactive clones in the peripheral B cell repertoire. Nevertheless, in normal circumstances, functional peripheral tolerance compensates for impaired central tolerance by

suppressing autoreactive clones in the pre-immune B cell pool to prevent humoral autoimmunity<sup>9</sup>.

It is unclear whether and how defects in RAG1/RAG2 impact peripheral B cell tolerance. Expansion of autoreactive B cells and spontaneous autoantibody production occur in mouse models of pRD, implying broken tolerance<sup>10,11</sup>. Patients manifesting with late-onset phenotype of pRD with immune dysregulation, termed ‘combined immune deficiency with granuloma/autoimmunity’ (CID-G/AI)<sup>12</sup> are present with multiorgan autoimmune disease with high titers of serum autoantibodies, including those targeting cytokines<sup>5</sup>. The remnant recombinase activity only partially correlates with the clinical phenotype<sup>13,14</sup> and the same RAG genetic variant, even within the same family, can result in a spectrum from asymptomatic to variable autoimmunity<sup>15,16</sup>, which may worsen with age and exposure to environmental antigens<sup>3,5,17–22</sup>. Accordingly, chronic Toll-like receptor (TLR) stimulation mimicking viral infection in a mouse model resulted in a broadening autoantibody profile<sup>5</sup>.

A full list of affiliations appears at the end of the paper.

Collectively, these indicate that, although *RAG1* and *RAG2* are expressed in developing B lymphocytes in the BM, they may impact B cell development and tolerance filters indirectly in the periphery. Here, in a cohort of patients with pRD we describe impaired primary BCR repertoire formation with remarkable alterations in the composition of B cell subsets, along with widespread, promiscuous activation that favors extrafollicular destiny and expansion of poly/autoreactive B cell clones in the periphery. Our results shed light on the mechanisms underlying complex immune dysregulation induced by pRD that affects multiple tolerance checkpoints and B cell fate in the periphery.

## Results

**Genetic and clinical features of patients with pRD.** The pRD cohort included a 5-month-old asymptomatic male (P1)<sup>21</sup> and 15 patients with a CID or CID-G/AI phenotype (P2–16) (Supplementary Table 1). Eleven patients carried *RAG1* (7 compound heterozygous and 4 homozygous) and 5 patients carried *RAG2* (3 compound heterozygous and 2 homozygous) variants, for a total of 16 *RAG1* and 8 *RAG2* distinct mutant alleles (Extended Data Fig. 1a). Pathogenicity was assigned based on combined assessment of in vitro recombination activity assays<sup>2,3</sup> and curated data obtained from ClinVar database and/or analysis following guidelines of American College of Medical Genetics and Genomics<sup>23</sup> and the Association for Molecular Pathology (Extended Data Fig. 1b and Supplementary Table 2).

All patients displayed profound lymphopenia as compared to aged-matched healthy ranges<sup>24</sup> (Extended Data Fig. 1c–f), except P13 who had chronic Epstein–Barr virus (EBV) and Cytomegalovirus (CMV) viremia with lymphoproliferation<sup>25</sup>. Asymptomatic P1 was considered to be antigen-naïve (pRD-N), whereas symptomatic P2–16 were grouped as antigen-experienced patients (pRD-Ag). P1 remained CMV negative and showed no clinical or laboratory signs of infections until successful hematopoietic stem cell transplantation<sup>21</sup>. All patients with pRD-Ag had upper and/or lower respiratory tract infections, including bronchiectasis in eight cases. Seven patients had one or a combination of adenovirus or herpesvirus infections (EBV, CMV, HSV and varicella). Ten patients had autoimmunity and three patients had granulomas affecting lung, skin and/or spleen (Extended Data Fig. 1b).

**Diverse autoantibody profiles in patients with pRD.** We detected autoantibodies in 11 plasma samples of 13 patients tested by immunofluorescent analysis (IFA) on HEp-2 cell slides with various intensities (very bright, bright, intermediate and low positive; 1, 4, 4 and 2 patients, respectively), whereas healthy controls (HCs) showed no or low positive staining (Extended Data Fig. 2a). Staining patterns included homogeneous nuclear (P11 and P14), speckled cytoplasmic (P1, P2, P4, P8, P9, P12 and P13) and cytoplasmic reticular/mitochondrial (P3 and P16). Quantitative image analysis confirmed

stronger cytoplasmic and nuclear staining in patients compared to HCs (Extended Data Fig. 2b,c, respectively). Eleven patients from 15 produced IgG autoantibodies against at least one specific antigen as tested by ELISA (defined as *z* score >2) and autoantibody levels against nine antigens were significantly higher in patients compared to HCs (Extended Data Fig. 2d). IgG autoantibodies to interferon (IFN)- $\alpha$ , IFN- $\omega$  and/or interleukin (IL)-12, a hallmark of pRD<sup>5,26</sup>, were present in ten patients with pRD-Ag (newly detected in four patients and previously published in six cases<sup>5</sup>) but not in pRD-N (Extended Data Fig. 2e). We also detected VH4-34-encoded IgM 9G4 antibodies that recognize polysaccharide antigens in red blood cells<sup>27</sup> in eight patients (Extended Data Fig. 2f); hence, the presence of a wide range of IgM and IgG autoantibodies indicates a failed B cell tolerance in pRD.


**Dysregulated peripheral B cell maturation and activation.** To assess peripheral B cell subsets, we performed unsupervised high-dimensional analysis from the peripheral blood of patients with pRD (Extended Data Fig. 3a–f). We identified 16 distinct metaclusters (M0–15), each corresponding to a unique B cell population with a specific surface marker expression pattern (Fig. 1a). Visualization of the B cell compartment composition by the 16 metaclusters with *t*-distributed stochastic neighbor embedding (*t*-SNE) indicated remarkable reduction in M15 and M10, whereas the M7–9 and M11–13 populations were expanded in pRD when compared to HCs (Fig. 1b).


Quantitative analysis confirmed the profound reduction of M15 (CD27-IgD<sup>+</sup>CD38<sup>hi</sup>CD24<sup>+</sup>IgM<sup>hi</sup>CD21<sup>int</sup>) corresponding to transitional B cells and M10 (CD27-IgD<sup>+</sup>CD38<sup>int</sup>CD24<sup>int</sup>IgM<sup>hi</sup>CD21<sup>hi</sup>), corresponding to mature resting naïve B cells in healthy individuals<sup>28</sup>, referred to as ‘CD38<sup>int</sup>’ in pRD when compared to HCs (Fig. 1c).

Notably, three CD27-IgD<sup>+</sup>CD38<sup>lo/-</sup> metaclusters, M7–9, were expanded in patients. Specifically, M7 and M8 were identified as new specific B cell subsets (CD27-IgD<sup>int</sup>CD38<sup>lo</sup>CD24<sup>+</sup>IgM<sup>int</sup>CD21<sup>hi</sup> and CD27<sup>lo</sup>IgD<sup>+</sup>CD38<sup>-</sup>CD24<sup>-</sup>IgM<sup>+</sup>CD21<sup>int</sup>, respectively) as these populations have not been described in humans, neither in healthy nor pathological conditions (Fig. 1c). The third CD27-IgD<sup>+</sup>CD38<sup>lo/-</sup> population (M9) was phenotypically identical to the recently described ‘activated naïve’ B cells (CD27-IgD<sup>hi</sup>CD38<sup>-</sup>CD24<sup>-</sup>IgM<sup>+</sup>CD21<sup>lo</sup>)<sup>28,29</sup>. As M7–9 became the predominant fraction of the CD27-IgD<sup>+</sup> compartment in pRD, we collectively referred to them as CD38<sup>-</sup> in our further investigations.

Among CD27-expressing metaclusters (conventional memory compartment and collectively referred as CD27<sup>+</sup>) we identified M11–14 that expressed IgM, therefore representing non-switched memory (NSM) B cells. M12 corresponded to NSM resting cells (CD27<sup>+</sup>IgD<sup>int</sup>CD38<sup>-</sup>CD24<sup>hi</sup>IgM<sup>+</sup>CD21<sup>hi</sup>) and was expanded in pRD, whereas M14 represented ‘pre-switched memory B cells’ (CD27<sup>+</sup>

**Fig. 1 | Immunophenotyping of peripheral blood B cells.** **a**, Automated B cell subset identification by FlowSOM. Minimal spanning trees of a representative HC and a patient with pRD are shown. Metaclusters, corresponding to individual B cell subsets are indicated by the background color of the nodes, numbers (M0–15) and marker expression pattern. **b**, B cell subset composition. Metaclusters from concatenated live B cells of four HCs and four patients with pRD were projected onto *t*-SNE space and assigned as in **a**. **c**, Frequencies of the specific B cell subsets. Circles represent antigen-experienced donors, HCs (HC-Ag, *n* = 18) and patients with pRD (pRD-Ag, *n* = 13); triangles represent antigen-naïve infant donors (HC-N, *n* = 4; pRD-N *n* = 1). Subsets comprising Trans, CD38<sup>int</sup>, CD38<sup>+</sup>, CD38<sup>-</sup>, CD27<sup>+</sup>, DN and ASC populations are depicted with different backgrounds. Statistical analyses were performed on individuals with antigens (HC-Ag versus pRD-Ag) (Mann-Whitney *U*-test with Holm–Šidák multiple comparison). Asterisks indicate new B cell subsets for **a–c**. **d**, Activation of peripheral blood B cells. Surface expression of CD69, CD25, HLA-DR, CD80, CD86, CD21 and CXCR5 in CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells is shown as histograms. Filled gray histograms depict the expression of each marker on the total B cells from an HC. Dark gray and red lines represent the expressions of each marker in the indicated compartments (CD38<sup>int</sup>, CD38<sup>-</sup> or CD27<sup>+</sup>) from an HC and a patient with pRD, respectively. Geometric mean fluorescence intensities (gMFIs) are indicated for each HC (black) and pRD B cell subsets (red) and HC total B cells (gray). **e**, Expression of activation markers. gMFI of each marker from CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> compartments were normalized by donors to the gMFIs of the total B cells from the HC(s) used in each experiment. Data are shown as mean  $\pm$  s.e.m. with individual values. Therefore, changes in the expression by compartments in HC-Ag (gray, *n* = 14) and patients with pRD-Ag (red, *n* = 6–8) are shown as relative to 1 (green dashed line), which represents marker expression level in the total B cells of HCs. Data were analyzed by Mann-Whitney *U*-test.





**Fig. 2 | T-bet<sup>+</sup> B cells.** **a**, Detection of CD19<sup>hi</sup>CD21<sup>lo</sup> B cells. **b,c**, Gating for CD19<sup>hi</sup>CD21<sup>lo</sup> B cells in a representative HC-Ag and patient with pRD-Ag. Fraction of CD19<sup>hi</sup>CD21<sup>lo</sup> B cells in total (**b**) and CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells (**c**) in HC-Ags (*n* = 14) and patients with pRD-Ag (*n* = 6). **d**, Detection of ABCs. Gating for ABCs in a representative HC-Ag and patient with pRD-Ag. **e,f**, Fraction of ABCs in total (**e**) and CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells (**f**) in HC-Ags (*n* = 14) and patients with pRD-Ag (*n* = 6). **g**, Distribution of ABCs in conventional and CD19<sup>hi</sup>CD21<sup>lo</sup> B cells. Contour plots show total B cells (gray), gate depicts CD19<sup>hi</sup>CD21<sup>lo</sup> B cells and ABCs are overlaid (green) in a representative HC-Ag and patient with pRD-Ag. **h**, Correlation between CD19<sup>hi</sup>CD21<sup>lo</sup> B cells and ABCs. Linear regression line is shown with 95% confidence intervals, Pearson *r* and *P* values are shown. Data were obtained from HC-Ags (gray, *n* = 14) and patients with pRD-Ag (red, *n* = 6). **i**, T-bet expressions in total B cells are shown as gMFIs. **j,k**, Detection (**j**) and fraction (**k**) of CD21<sup>+</sup>CD11c<sup>-</sup>, CD21<sup>lo</sup>CD11c<sup>-</sup> and CD21<sup>lo</sup>CD11c<sup>+</sup> B cell populations. Gating is shown in a representative HC-Ag and patient with pRD-Ag. **l,m**, T-bet expression in CD21<sup>+</sup>CD11c<sup>-</sup>, CD21<sup>lo</sup>CD11c<sup>-</sup> and CD21<sup>lo</sup>CD11c<sup>+</sup> B cells in a representative HC-Ag and patient with pRD-Ag (**l**) and shown as gMFIs (**m**). **n-p**, Expressions of FcRL4, FcRL5, CD85j and CXCR3 (**n**), CD95 (**o**) and BAFF-R (**p**) in total B cells are shown as gMFIs. Data for **i-p** were obtained from HC-Ags (*n* = 7-14) and patients with pRD-Ag (*n* = 4-5). Data for **b,c,e,f,k-o** are shown as mean ± s.e.m. with individual values depicted. Statistical analyses were performed using two-sided unpaired Student's *t*-test for data on **b,c,e,f,l-o** or Mann-Whitney *U*-test with multiple comparison (Holm-Šidák method) for **k**. **q**, Overlaid markers (CD19, CD4, T-bet and 4,6-diamidino-2-phenylindole (DAPI)) in a HC-Ags and patients with pRD-Ag. Magnification ×10. Follicular (Fo) and extrafollicular (EF) areas are indicated that were used for higher magnifications. **r**, T-bet expression by Fo and EF areas. Magnification ×60. **s**, T-bet expression in B cells by Fo and EF areas. Arrow shows T-bet<sup>+</sup> B cells. Magnification ×60.

IgD<sup>lo</sup>CD38<sup>int</sup>CD24<sup>hi</sup>IgM<sup>+</sup>CD21<sup>hi</sup>)<sup>28</sup>. In addition, we defined M11 and M13 as new NSM cells (CD27<sup>+</sup>IgD<sup>+</sup>CD38<sup>-</sup>CD24<sup>hi</sup>IgM<sup>+</sup>CD21<sup>-</sup> and CD27<sup>+</sup>IgD<sup>+</sup>CD38<sup>lo</sup>CD24<sup>lo</sup>IgM<sup>+</sup>CD21<sup>-</sup>, respectively) that were significantly expanded in pRD (Fig. 1c). CD27<sup>+</sup>IgD<sup>lo/-</sup>IgM<sup>lo/-</sup> switched memory (SM) fraction harbored the resting SM B cells (M1, CD27<sup>+</sup>IgD<sup>lo</sup>CD38<sup>int</sup>CD24<sup>+</sup>IgM<sup>lo</sup>CD21<sup>hi</sup>)<sup>28</sup>, which were significantly decreased in pRD and M2–3 (CD27<sup>+</sup>IgD<sup>lo</sup>CD38<sup>-</sup>CD24<sup>+</sup>IgM<sup>-</sup>CD21<sup>hi</sup> and CD27<sup>+</sup>IgD<sup>lo</sup>CD38<sup>-</sup>CD24<sup>int</sup>IgM<sup>-</sup>CD21<sup>lo</sup>, respectively) (Fig. 1c). These alterations in the CD27<sup>+</sup> populations resulted in the dominance of NSM over SM B cells in pRD when compared to HCs.

We identified M6 (CD27<sup>-</sup>IgD<sup>-</sup>CD38<sup>int</sup>CD24<sup>int</sup>IgM<sup>int</sup>CD21<sup>hi</sup>) and M4 (CD27<sup>-</sup>IgD<sup>-</sup>CD38<sup>-</sup>CD24<sup>-</sup>IgM<sup>int</sup>CD21<sup>lo</sup>), as CD27<sup>-</sup>IgD<sup>-</sup> double negative (DN) subsets, corresponding to DN1 and DN2, respectively<sup>28</sup>. Notably, DN1:DN2 (M6:M4) ratio in pRD was skewed toward DN2 (M4) similarly to what is seen in systemic lupus erythematosus<sup>30</sup> (Fig. 1c). Finally, a decrease in pRD M0 (antibody-secreting cells (ASCs), CD27<sup>hi</sup>IgD<sup>-</sup>CD38<sup>hi</sup>CD24<sup>-</sup>IgM<sup>lo</sup>CD21<sup>int</sup>) was also noticed, although the difference was not statistically significant.

In absolute counts, most B cell subsets were decreased in pRD compared to HCs, reflecting their B cell lymphopenia; however, M9 'activated naive' B cells were significantly elevated (Extended Data Fig. 3g). Analysis of B cell subsets with conventional standard gating (Extended Data Fig. 4a) confirmed that transitional, mature resting naive and SM B cells, were reduced, whereas atypical CD38<sup>-</sup> naive B cells and marginal zone-like B cells were greatly expanded in pRD (Extended Data Fig. 4b–d).

In addition, all three B cell subsets (CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup>) defined above displayed increased activation status in pRD as assessed by the expression of CD69, CD80 and CD86 (Fig. 1d,e). We also found significantly elevated levels of CD25 and HLA-DR in the CD38<sup>int</sup> and the CD27<sup>+</sup> compartments of the patients, respectively (Fig. 1d,e). Decrease in the expression of CD21, indicating previous history of B cell activation<sup>31</sup>, was detected in the patients, offering further evidence of promiscuous B cell activation in pRD (Fig. 1d,e). Finally, we detected significantly lower expression of the follicle homing receptor, CXCR5, on each B cell subset of patients with pRD compared to HCs (Fig. 1d,e).

In summary, the B cell compartment in patients with pRD-Ag displayed remarkable activation and subset dysregulation with expansion of non-conventional B cells. Notably, asymptomatic P1 (pRD-N) did not show these changes, thus, dysregulated B cell maturation with promiscuous activation in pRD is likely a dynamic process that worsens with age and disease state, implying the role of environmental triggers.

**Expansion of non-conventional T-bet<sup>+</sup> B cells.** As a clinically established hallmark of immune dysregulation<sup>32</sup>, we documented substantial expansion of CD19<sup>hi</sup>CD21<sup>lo</sup> B cells in pRD (Fig. 2a,b), which were equally distributed among CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells (Fig. 2c). The CD11c<sup>hi</sup>CXCR5<sup>lo</sup> population, resembling

murine age-associated B cells (ABCs)<sup>33</sup>, was also present at a higher frequency in pRD and were equally enriched in the CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> compartments (Fig. 2d–f). Although both HC and pRD ABCs contribute to a smaller fraction of total B cells than CD19<sup>hi</sup>CD21<sup>lo</sup> cells, they fully overlap with the latter, indicating that ABCs are part of the CD19<sup>hi</sup>CD21<sup>lo</sup> fraction (Fig. 2g), hence, they expand in parallel in pRD (Fig. 2h).

In addition to these surface markers, transcription factor T-bet serves an ultimate marker for ABCs<sup>33,34</sup>. T-bet was indeed expressed at a higher level in pRD B cells than in HCs (Fig. 2i and Extended Data Fig. 4e). Although CD21<sup>lo</sup>CD11c<sup>-</sup> and CD21<sup>lo</sup>CD11c<sup>+</sup> cells were more abundant in pRD than in HCs (Fig. 2j,k) and T-bet expression was increased toward the latter, it was equally elevated in HCs and pRD, indicating that T-bet is induced at similar level in the corresponding populations of healthy individuals or patients (Fig. 2l,m). By assessing T-bet in CD38<sup>int</sup>, CD38<sup>-</sup>, CD27<sup>+</sup> and DN B cells, we found increased expression in earlier B cell stages (CD38<sup>int</sup> and CD38<sup>-</sup>) in pRD, whereas its levels were comparable in CD27<sup>+</sup> and DN B cells with those of HCs (Extended Data Fig. 4f–h) in pRD when measured.

In addition, FcRL4, FcRL5, CD85j and CXCR3 ABC-specific marker expressions were higher in total B cells (Fig. 2n) and CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> populations (but not in DN cells) in pRD compared to HCs (Extended Data Fig. 4i). Of note, CD95 expression was increased, whereas B cell-activating factor receptor (BAFF-R) expression was decreased in total B cells (Fig. 2o,p) and in each individual subset (Extended Data Fig. 4j,k) in pRD compared to HCs.



Examination of the spleen biopsy sample of a pRD patient (P5) confirmed white pulp hyperplasia and the presence of previously described non-necrotic epithelioid granulomas<sup>35</sup>, revealed remarkable reactive and giant follicles, marginal zone hyperplasia and periarteriolar T-zone hyperplasia, which scored high (12) in comparison to that observed in a previous cohort with common variable immunodeficiency and splenectomy<sup>36</sup> (Extended Data Fig. 5a,b). Lymphoid hyperplasia was notable for expansion of B cells, especially CD21<sup>lo</sup> cells outside the germinal centers (Extended Data Fig. 5c,d) along with follicular helper T (T<sub>FH</sub>) cell accumulation (Extended Data Fig. 5e,f). Compared to the HC, spleen follicles from P5 were hyperplastic and irregularly shaped and they occupied a larger proportion of the splenic tissue (Extended Data Fig. 5g). Notably, we detected T-bet<sup>+</sup> B cells in the follicular areas of the patient, whereas they were absent in those of the HC (Fig. 2q–s and Extended Data Fig. 5h). Although T-bet<sup>+</sup> B cells were detected in the extrafollicular regions of both P5 and the HC, they were more abundant in the patient (Fig. 2q–s and Extended Data Fig. 5i). Thus, expansion of T-bet<sup>+</sup> B cells in the circulation, follicular and extrafollicular spaces is a unique feature of pRD and represents an additional marker of B cell dysregulation.

**Restricted BCR repertoire diversity.** The prominent alterations in the subset distribution and activation of B cells in pRD

**Fig. 3 | BCR repertoire characteristics in patients with pRD.** **a**, Treemap representation of the diversity and clonality of immunoglobulin heavy-chain repertoires. Each rectangle represents an immunoglobulin heavy-chain clonotype and the size of rectangles is proportional to the relative frequency of each clone in the entire repertoire. Distinct clones sharing the same V<sub>H</sub> gene are displayed using altered brightness of the same hue indicated by the color scale. Thick borders and colors assign clones into the corresponding V<sub>H</sub> gene families. Each treemap represents the most abundant 2,500 clones. One antigen-naive healthy infant (HC-N), three representative antigen-exposed HCs (HC-Ag), the antigen-naive infant patient (pRD-N) and the antigen-exposed patients with pRD (pRD-Ag, n = 5) are shown. Labels on the left show participant IDs. Labels on the top indicate B cell compartments. No sufficient amount of CD38<sup>-</sup> cells was obtained from the infant donors and P9 for sequencing. **b**, Ratio of unique and total sequence counts. **c–e**, Shannon's H (**c**), Gini-Simpson (1 – D) (**d**) and Diversity 50 (D50) (**e**) diversity indices. **f**, Cumulative frequency of the ten most abundant clones. **g**, Frequency of SHM in the V segment. Bars represent mean ± s.e.m. for each group with the individual values indicated. **h**, Mutation distribution. Graph shows replacement mutation frequencies in CDR and FR regions in CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells. **i**, Isotype distribution. Stacked columns show the percentage of each Ig class in each repertoire by individuals and B cell compartments. Numbers depict participant IDs. Data for each analysis were obtained from HC-Ags (n = 5), HC-N (n = 1), pRD-Ag (n = 5) and pRD-N (n = 1). Statistical analyses were performed only on individuals with antigens (HC-Ag versus pRD-Ag) using a Mann-Whitney U-test. For **i**, unswitched (IgD + IgM) and switched (IgG + IgA + IgE) sequences were compared.

prompted us to evaluate the BCR repertoire composition in sorted CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> populations (Extended Data Fig. 6a,b and Supplementary Table 3). As visualized on treemaps, CD38<sup>int</sup> B cells from pRD expressed oligoclonal repertoires with

prominent expansion of 1 to 5 specific V<sub>H</sub> gene families (Fig. 3a). These expanded V<sub>H</sub> families were usually dominated by a few expanded unique clones. In contrast, CD38<sup>-</sup> and CD27<sup>+</sup> repertoires were more similar to those of HCs except P13, whose repertoires were



dominated VH1-2 genes. Restricted diversity with oligoclonality of the CD38<sup>int</sup> subset in pRD was further supported by the low ratio of unique to total sequences, lower Shannon's H and increased Gini-Simpson indices in the CD38<sup>int</sup> BCR repertoires of the patients, compared to HCs (Fig. 3b–d). Of note, fewer than 5% of the unique sequences accounted for 50% of the total CD38<sup>int</sup> repertoires in patients P1, 9, 13, 14 and 16 (Fig. 3e) and the most common ten clones comprised a substantial fraction of their CD38<sup>int</sup> repertoires (mean  $\pm$  s.e.m.,  $17.13 \pm 6.071$ ), in contrast to HCs (mean  $\pm$  s.e.m.,  $1.45 \pm 0.39$ ) (Fig. 3f). Together, these data demonstrate decreased diversity and expansion of certain clones in the CD38<sup>int</sup> repertoire of patients with pRD, whereas their CD38<sup>-</sup> and CD27<sup>+</sup> compartments seemed to be substantially more diverse. Regarding V<sub>H</sub>, D<sub>H</sub> and J<sub>H</sub> gene segment utilization, we found diversified repertoires in the patients (except in P13) (Extended Data Fig. 7a). In addition, despite the high plasma titer of IgM-type 9G4 antibodies in patients, we did not find elevated frequency of V<sub>H</sub>4–34-carrying clones in the pRD-Ag repertoires; however, it was expanded in the patient with pRD-N (20.92%). As previously published<sup>14</sup>, distal J<sub>H</sub>5 and J<sub>H</sub>6 gene segments were significantly less frequent in all three compartments repertoires reflecting the RAG activity impairment in the patients (Extended Data Fig. 7a).

Hence, in connection to their altered phenotype and activation of pRD B cells we identified severe diversity restrictions in the pre-immune repertoire of the patients.

**Aberrant somatic diversification.** Next, we identified a uniformly increased level of somatic hypermutation (SHM) in the CD38<sup>int</sup> repertoire of patients with pRD-Ag despite that these cells should express the germline version of their V segments with nearly no mutations, as found in the HCs (Fig. 3g). This finding indicates that although CD38<sup>int</sup> B cells in patients with pRD were phenotypically defined as mature naive resting B cells (IgD<sup>+</sup>CD21<sup>+</sup>CD24<sup>int</sup>CD27<sup>-</sup>CD38<sup>int</sup>), some may represent Ag-experienced B cells and cannot be considered bone fide naive cells. Of note, continuum expression of CD27 did not segregate naive and memory B cells with high confidence in pRD (Extended Data Fig. 3g; CD27-IgD plots). Notably, although the patient with pRD-N already acquired some SHM in the CD38<sup>int</sup> compartment, it did not reach the level seen in patients with pRD-Ag, suggesting that the unusually early-onset SHM of CD38<sup>int</sup> B cells is a progressive phenomenon in pRD. Notably, although the CD38<sup>-</sup> compartment represent phenotypically naive B cells (IgD<sup>+</sup>CD27<sup>-</sup>), they displayed a similarly elevated level of SHM whether they were obtained from HCs or patients with pRD, suggesting that despite their different abundance in the peripheral blood of HCs and pRD, they share comparable mutational diversification characteristics. Although SHM was elevated in the CD38<sup>int</sup> and CD38<sup>-</sup> compartments of patients, its level remained lower in their CD27<sup>+</sup> repertoire compared to HCs, indicating impaired mutational diversification and affinity maturation in pRD. As expected, SHM levels in the CD27<sup>+</sup> repertoire of both the infant patient and the age-matched control (pRD-N and HC-N, respectively) were similarly lower than in Ag-experienced individuals. SHM frequency was substantially higher in the complementarity-determining regions (CDRs) than in the framework regions (FRs) of the pRD CD38<sup>int</sup> B cells, suggesting antigen-driven selection (and remained close to zero in the CDRs and FRs of HCs) (Fig. 3h). This pattern was preserved in the CD38<sup>-</sup> and CD27<sup>+</sup> compartments; however, SHM frequency in the latter did not reach that of corresponding HCs, further confirming the absence of proper memory response in pRD (Fig. 3h). Of note, mutations were more frequent in the activation-induced cytidine deaminase (AID) WRCY/RGYW hotspot of the CD38<sup>int</sup> and CD38<sup>-</sup> compartments in pRD than in HCs (Extended Data Fig. 7b,c).

Regarding immunoglobulin class-switch recombination (CSR), we detected an abundance of switched transcripts in CD38<sup>int</sup>

repertoires in pRD although with substantial inter-individual variability, whereas it remained negligible in HCs (Fig. 3i). This implies the unforeseen inclusion of antigen-experienced B cells in the phenotypically naive compartment in pRD. In connection to this, we detected unusual co-presence of IgM and IgG on the surface of the patients' B cells (Extended Data Fig. 7d,e). On the other hand, CSR was significantly lower in the CD27<sup>+</sup> repertoires of patients compared to HCs (Fig. 3i).

In summary, we found somatic diversification in the CD38<sup>int</sup> compartment and subpar SHM and CSR in the CD27<sup>+</sup> compartment of the patients with pRD; hence, these findings provide additional evidence for early widespread and dysregulated B cell activation in pRD, with predisposition to impaired humoral effector function, consistent with our previous findings of decreased fraction and number of SM B cells.


**Defective tolerance that worsens with age.** Frequencies of the polyreactive clones in new emigrant (NE) transitional and CD38<sup>int</sup> B cell compartments are measures of the efficiency of central and peripheral B cell tolerance, respectively<sup>6</sup>. Thus, we assessed the abundance of polyreactive clones by analyzing the reactivity of recombinant antibodies cloned from single-sorted NE and CD38<sup>int</sup> B cells (Extended Data Fig. 8a). Due to the scarcity of circulating NE cells in the patients with pRD-Ag, we managed to assess the central tolerance efficiency only in the asymptomatic infant (P1). We detected remarkably higher frequency of polyreactive clones compared to published age-matched individuals with functional central tolerance<sup>37</sup> (Extended Data Fig. 8b,c). We also found decreased usage of distal J<sub>κ</sub> gene segments (J<sub>κ</sub>4 and 5) in the patients compared to HCs (Extended Data Fig. 8d), (but not in the distal J<sub>λ</sub> gene segments (J<sub>λ</sub>3); Extended Data Fig. 8e). Besides impaired V(D)J recombination, this observation also illustrates defective receptor editing providing additional evidence for impaired central tolerance in pRD. In contrast, we did not find significant disturbance in the proportion of κ and λ light-chain expression (another potential marker of receptor editing) in either of the B cell compartments of the patients, except transitional cells (Extended Data Fig. 8f–h).

Next, we found elevated fraction of polyreactive clones in the CD38<sup>int</sup> compartment in all patients compared to HCs, demonstrating a uniform peripheral tolerance defect in pRD (Fig. 4a–c and Supplementary Table 3). We noted significant difference ( $P=0.031$ ; Student's *t*-test) in the frequency of polyreactive clones between children ( $n=3$ ) and adults ( $n=3$ ) with pRD ( $21.1 \pm 2.0\%$  mean  $\pm$  s.e.m.; range 18.8–25.0% and  $32.7 \pm 3.0\%$  mean  $\pm$  s.e.m.; range 27.3–37.5%, respectively). Of note, a fraction of the analyzed clones from P12, P14 and P16 carried mutations in their V segment, indicating ongoing somatic diversification and therefore, cannot be considered as resting mature B cells. Nevertheless, the proportion of polyreactivity in unmutated clones was still uniformly higher in all patients compared to HCs, confirming the profound peripheral tolerance defect. HEp-2 reactivity of the expressed clones confirmed peripheral tolerance impairment in pRD (Fig. 4d,e). In addition, HEp-2 cell-based IFA revealed distinct binding of the polyreactive clones (cytoplasmic fibrillar filamentous (P12.1D3), multiple nuclear dots (P13.2G5), cytoplasmic dense speckled (P14.1A10) and homogeneous nucleolar (P14.5B7)), suggesting that although they are polyreactive, they bear preferential self-specificities (Fig. 4f).


In summary, these data demonstrate that B cell tolerance is defective in pRD, it worsens with age and likely with chronic antigen exposure.

**Diversification and persistence of polyreactive clones.** Because our findings imply that polyreactive B cell clones escape both central and peripheral tolerance checkpoints and survive, we aimed to evaluate their trajectories and determine whether they reach effector compartments. Therefore, we traced each expressed sequence





**Fig. 4 | Impaired peripheral B cell tolerance in patients with pRD. a**, Polyreactivity of CD38<sup>int</sup> B cells. Antibodies cloned from CD38<sup>int</sup> B cells were tested for anti-double-stranded DNA (dsDNA), insulin and lipopolysaccharide (LPS) reactivity in serial dilution. Binding of 20 randomly selected clones is shown on each graph. Thick black lines with blue circles show binding of the two positive controls used in each assay to determine the threshold for positive reactivity (mean of positive controls minus 2 s.d. at 1.0  $\mu\text{g ml}^{-1}$ ). Threshold for positive reactivity is shown by a green dashed line. **b**, Frequency of polyreactive clones by individuals. Pie charts depict the frequency of non-polyreactive (white) and polyreactive (red) clones for each individual and the percentage of polyreactive clones are shown. The fraction of sequences carrying at least two mutations compared to their corresponding germline versions is depicted by dotted patterns. **c**, Frequency of polyreactivity. **d**, HEp-2 reactivity of CD38<sup>int</sup> B cell clones. Cloned antibodies were tested in 5.0  $\mu\text{g ml}^{-1}$  concentration for anti-HEp-2 cell line lysate with the two positive controls used in each assay. Blank corrected absorbance values were normalized with the mean of positive controls minus 2 s.d. and values above 1 (green dashed line) were considered positive for HEp-2 reactivity. **e**, Frequency of HEp-2 reactivity. For **c–e** data are shown as mean  $\pm$  s.e.m. with individual values and statistical analyses performed on individuals with antigens (HC-Ag versus pRD-Ag) using a two-sided unpaired Student's *t*-test. Antibodies were cloned and tested from HC-Ags ( $n=3$ ), pRD-N ( $n=1$ ) and patients with pRD-Ag ( $n=5$ ). The total number of B cell clones tested is indicated for each individual in **b**. **f**, HEp-2 immunofluorescence. Cloned antibodies were used in HEp-2 immunofluorescence assays to show target antigen distribution. Representative images for negative and positive stainings are shown from one HC-Ag and three pRD-AG individuals. Individual and antibody clone IDs are shown. Magnification  $\times 16$ .



**Fig. 5 | Expansion and diversification of polyreactive clones.** **a**, Clones with descendants in total repertoire. Graph shows the number of the in vitro expressed clones by donors (gray bars). Number of clones with identified descendants in total repertoire are depicted with deep red. Data are shown from HC-Ags ( $n=3$ ), pRD-N ( $n=1$ ) and patients with pRD-Ag ( $n=5$ ) with individual IDs indicated. **b**, Contribution of descendants to repertoire. Fraction of the descendants of clones in total repertoires are shown by individuals. Descendants of the polyreactive and non-polyreactive clones are depicted with filled and striped bars, respectively. **c**, Compartmental distribution of the descendants. The contribution of the descendants of each clone to the total repertoires are shown in the indicated individuals by CD38<sup>int</sup> (blue); CD38<sup>-</sup> (red) and CD27<sup>+</sup> (green) compartments. Clone IDs are shown; deep red and black represents polyreactive and non-polyreactive clones, respectively. Striped bars for P14 represent clones identified in repertoires obtained 1 year later after isolation of original clones. Clones with shared descendants in the two time points are indicated with bold. **d**, Single nucleotide mutations in clones. Average number of mutations in the V segment by individuals are shown as mean  $\pm$  s.e.m. for HCs ( $n=3$ ), pRD-Ag ( $n=5$ ) and pRD-N ( $n=1$ ) with individual values depicted. Statistical analyses were performed on individuals with antigens (HC-Ag versus pRD-Ag) using a Mann-Whitney  $U$ -test. **e**, Phylogenetic lineage trees of expanded clonotypes. Immunoglobulin trees represent expansion of individual clonotypes by their SHM profile. Putative unmutated common ancestors (UCAs) are depicted by squares, arrowhead indicates the original in vitro expressed sequence, descendants are shown by CD38<sup>int</sup> (blue), CD38<sup>-</sup> (red) or CD27<sup>+</sup> (green) compartments and the color of the nodes indicates antigen selection strength (blue to deep red). Size of the nodes represent sequence abundance. The number of the nucleotide difference between adjacent sequences and the isotype of each sequence are shown. Lineages derived from polyreactive or non-polyreactive CD38<sup>int</sup> clones are depicted with deep red or black, respectively. Orange line indicates descendants from second time point for P14.

and their related descendants in the CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> repertoires. Notably, we identified related clones in the CD38<sup>int</sup> BCR repertoires of P1, P12, P14, P16 ( $n=24.8 \pm 5.4$  clones per donor) (Fig. 5a). Two of these patients (P1 and P14) had persistent

polyreactive and non-polyreactive clones that contributed to the entire sequence pool at a remarkable level (Fig. 5b). As expected, no related clones were identified in the naive or effector compartments of the HCs. In contrast, we detected simultaneous presence of

related clones in CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> compartments of three patients with pRD-Ag, whereas sister clones were only present in the CD38<sup>int</sup> compartment of the individual with pRD-N (Fig. 5c). Furthermore, longitudinal analysis of relatedness revealed durable presence of three distinct clones in P14 (1B5, 1C11 and 6E11) 1 year apart, with higher abundance in CD38<sup>-</sup> or CD27<sup>+</sup> compartments at the second time point. Collectively, these data indicate that certain polyreactive (and non-polyreactive) CD38<sup>int</sup> clones persist chronically in pRD.

The rate of SHM in the V region of the patients' clones was increased compared to those of HCs (Fig. 5d) (similarly to the full CD38<sup>int</sup> repertoire; Fig. 3g), reflecting activation due to potential antigen exposure. Mutation frequency was higher in patients with pRD-Ag, whereas it remained similar in the infant patient to that of HCs. Constructing phylogenetic immunoglobulin lineage trees of related clones (Fig. 5e) revealed remarkably expanded B cell lineages that consisted of  $7.59 \pm 11.03$  (mean  $\pm$  s.d., range 1–48) individual sequences in the patients. Of note, several descendants expressed switched transcripts such as IgG1\*03, IgG4\*01, IgG4\*04, IgA and IgE, which were more abundant among those of polyreactive clones, suggesting a potential role for polyreactivity in the accelerated somatic diversification. In connection with accumulating SHMs, we detected positive antigen selection in several lineages that was also more frequent in those originated from polyreactive CD38<sup>int</sup> clones. Notably, largely expanded individual clones likely harbored sequences with stronger antigen selection values and reached the CD27<sup>+</sup> compartment (P14 1C10, 1B5 and 1D3).

These data provide experimental evidence for the prominent B cell clonal expansion with notable intralinear somatic diversification by CSR and SHM in pRD. Descendants of several clones were simultaneously present in the CD38<sup>-</sup> or CD27<sup>+</sup> compartments, revealing intercompartmental expansion and persistence. Together, these findings demonstrate how polyreactive lineages persist, expand and diversify in pRD after escaping inefficient peripheral tolerance mechanisms.

**Intralinear diversification and clonal connectivity.** Prompted by the evidence that polyreactive B cells clonally expand, accumulate in CD38<sup>-</sup> and CD27<sup>+</sup> compartments and show intralinear diversification, we analyzed clonal trajectories at the full BCR repertoire level. In line with the previously observed oligoclonality (Fig. 3a–f), we detected remarkable clonal expansion in CD38<sup>int</sup> compartments of five patients (Fig. 6a,b), whereas those of HCs showed very uniform networks with each node of similar size, reflecting no intraclonal expansion. Notably, clonal expansion in pRD was not homogenous as indicated by lineages with numerous different related sequences (as opposed to lineages with single large nodes) and diversification occurred by SHM and CSR as already observed at the single-clone level (Fig. 5e). The symmetric structure of the expanded lineages with radial projections of the diversified sister




clones in patients indicates neutral drift-like clonal microevolution and likely the absence of specific antigen-driven positive selection; however, in some cases asymmetric branches containing enlarged nodes extruded from the core structure. These likely represent selective expansion of particular sequences due to possible positive selection pressure. Indeed, linking antigen selection strength values to the sequences revealed positive selections associated to several asymmetric branches with enlarged clonal size. In contrast, clonal expansion was less pronounced in the CD38<sup>-</sup> and CD27<sup>+</sup> compartments and mainly observed only in P13 and P16 (Fig. 6b and Extended Data Fig. 9a,b). Investigation of clonal sharing revealed intercompartmental lineage connections with promiscuous clonal overlap between CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> compartments in pRD, whereas the connections remained near zero in HCs (Fig. 6c and Extended Data Fig. 9c).


**Enhanced B cell activation signals.** Their activated phenotype and prominent expansion imply increased propensity of pRD CD38<sup>int</sup> B cells for differentiation to effector cells. Indeed, CD38<sup>int</sup> B cells from patients with pRD-Ag differentiated at higher frequency into CD27<sup>+</sup>CD38<sup>lo</sup> or CD27<sup>hi</sup>CD38<sup>hi</sup> in vitro than those of HCs (Fig. 7a,b). Notably, HC CD38<sup>int</sup> B cells became more activated when cultured with patient's plasma in vitro, as detected by increased expression of CD25 and CD86 (Fig. 7c–e) compared to HCs. Thus, plasma from patients with pRD represents a unique pathogenic microenvironment that induces rapid and promiscuous B cell activation.

We detected significantly higher endotoxin concentrations in the patients' plasma compared to HCs (Fig. 7f) and 6 of 13 and 3 of 13 patients tested positive for EBV and CMV, respectively (Fig. 7g,h). The presence of these foreign antigens was associated with highly elevated soluble IL-2R plasma levels in pRD reflecting lymphocyte activation and inflammation (Fig. 7i). In addition, we found higher plasma levels of BAFF in pRD than in HCs (Fig. 7j). Of note, we also measured detectable levels of IFN- $\gamma$  (Fig. 7k) and IL-10 (Fig. 7l) in the plasma samples of several patients while they remained undetectable in HCs. These data together indicate that pRD establishes a unique milieu that favors promiscuous B cell activation.

**Robust T<sub>FH</sub> cell function.** Like B cells, T cells are also dysregulated in pRD and are characterized by decreased count, skewed toward activated memory cells and, specifically, suppressor capacity of regulatory T (T<sub>reg</sub>) cells is defective<sup>4,38</sup>. We confirmed decreased T<sub>reg</sub> cell frequency and naive-memory ratio; and found remarkable expansion of circulating T<sub>FH</sub> (cT<sub>FH</sub>) cells in our pRD cohort (Fig. 8a,b). Notably, all these T helper (T<sub>H</sub>) cell subsets were still normal in the asymptomatic patient with pRD-N. Of note, PD-1<sup>+</sup> T<sub>H</sub> cells were abundant in the spleen of a patient with pRD and uniformly distributed compared to an HC (Extended Data Fig. 10a–c). Assessment of naive, central memory, effector memory (EM) and terminally differentiated effector memory T (TEMRA) cells

**Fig. 6 | Clonal connectivity and diversification.** **a**, Clonal expansion with somatic hypermutation, isotype switches and antigen selection in CD38<sup>int</sup> compartment. Repertoire data were randomly downsampled to 2,500 unique sequences from CD38<sup>int</sup> compartments of each donor and plotted on lineage network diagrams. Nodes represent unique sequences, where the size of the nodes is proportional to the abundance of the given sequence in the repertoire on a logarithmic scale and lines depict clonal relatedness. Therefore, nodes in each cluster belong to the same clonotype and differ in mutations in their V segments. Accumulation of mutations (left), isotypes (middle) and antigen selection values (right) are shown for each clone as indicated below the diagrams. One representative adult HC-Ag, the infant pRD-N and the patients with pRD-Ag ( $n=5$ ) are shown, labels on the left indicate individual IDs. **b**, Clonotype size (intra-compartmental clonal connectivity). Average number of clonal connections by repertoires (CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup>) Data are shown as mean  $\pm$  s.e.m. for HC-N ( $n=1$ ), HC-Ag ( $n=5$ ), pRD-N ( $n=1$ ) and pRD-Ag ( $n=5$ ). Mann-Whitney *U*-test was performed on individuals who were Ag-experienced. **c**, Clonal sharing between CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> repertoires. The 10,000 randomly selected sequences from each repertoire were arranged on circular plots from a representative HC-Ag and patients with pRD-Ag. Numbers indicate sequence IDs; segmentation of rings indicates clonal size. Clones belonging to the same lineages in distinct compartments are connected depicting clonal connections. Colored connection lines indicate lineages accounting for sequences found in the largest clones up to 20% of total sequences. Plots are representative of a HC-Ag and pRD-Ag. Data from additional investigated individuals are shown in Extended Data Fig. 9c.





**Fig. 7 | B cell activation signals.** **a**, In vitro CD38<sup>int</sup> B cell differentiation. Sorted CD38<sup>int</sup> B cells were activated with CpG, CD40L and IL-21. Differentiated cells (CD27<sup>+</sup>CD38<sup>lo</sup> and CD27<sup>+</sup>CD38<sup>hi</sup>) were quantified on day 7. Experimental design is shown and contour plots are representative of an individual with HC-Ag and a patient with pRD-Ag from six independent experiment. **b**, Enumeration of effector cells. The proportion of CD27<sup>+</sup>CD38<sup>lo</sup> and CD27<sup>+</sup>CD38<sup>hi</sup> from HC-Ags ( $n=6$ ), pRD-N (P1) ( $n=1$ ) and patients with pRD-Ag ( $n=5$ ) are shown as percentage of total live B cells in the culture. **c**, Experimental design for testing B cell activation by plasma. Sorted CD38<sup>int</sup> HC B cells were cultured in vitro in the presence of IL-21 and plasma from either a patient with pRD-Ag ( $n=5$ ) or independent HC-Ag ( $n=5$ ) and analyzed on day 2 for CD25 and CD86 expression. **d**, Activation of sorted CD38<sup>int</sup> B cells with plasma. Surface expression of CD25 and CD86 are shown as overlaid histogram plots depicting representative samples of HC-Ag plasma-stimulated, patient with pRD-Ag plasma-stimulated and unstimulated HC. Dashed line indicated marker expression level on day 0. Expression levels are indicated as gMFs. **e**, Enumeration of B cell activation. Graphs show expression of CD25 and CD86 at day 0 and 2 days of stimulation with HC-Ags ( $n=5$ ) or patients with pRD-Ag ( $n=6$ ) plasma at the indicated plasma concentration in culture medium. Data for **d,e** were obtained from a single experiment performed on all plasma samples simultaneously. **f**, Plasma endotoxin levels. HC-Ags ( $n=13$ ), pRD-N (P1) ( $n=1$ ) and pRD-Ags ( $n=10$ ). **g,h**, Plasma virus levels. Epstein-Barr nuclear antigen and CMV titers were detected in the plasma of HC-Ags ( $n=15$ ), pRD-N (P1) ( $n=1$ ) and pRD-Ags ( $n=12$ ). **i**, Plasma soluble IL-2R levels. HC-Ags ( $n=11$ ), pRD-N (P1) ( $n=1$ ) and pRD-Ags ( $n=10$ ). **j**, Plasma BAFF levels. HC-Ags ( $n=20$ ), pRD-N (P1) ( $n=1$ ) and pRD-Ags ( $n=14$ ). **k,l**, Plasma IFN- $\gamma$  and IL-10. HC-Ags ( $n=11$ ), pRD-N (P1) ( $n=1$ ) and pRD-Ags ( $n=14$ ). Data are shown as mean  $\pm$  s.e.m. with individual values depicted on each graph. For statistical analysis Mann-Whitney  $U$ -test was performed for **b**; and two-sided unpaired Student's  $t$ -test was used for **e-l** to compare patients with pRD-Ag to individuals with HC-Ag.

confirmed a significant decrease in the proportion of naive cells and revealed the strong expansion of EM T<sub>H</sub> cells in pRD (Extended Data Fig. 10d,e). Of note, the proportion of PD-1<sup>hi</sup>ICOS<sup>hi</sup> cells was elevated in each of the investigated T<sub>H</sub> subsets of the patients (Fig. 8c,d) and the cT<sub>FH</sub> cells displayed an activated phenotype (Fig. 8c,d). This was further confirmed by the lower expression level of quiescence marker, CCR7, in the PD-1<sup>+</sup> fraction of the cT<sub>FH</sub> (and memory) cells in pRD (Fig. 8e,f). These phenotypic alterations of pRD cT<sub>FH</sub> cells were associated with reduced diversity of their TCR-V $\beta$  repertoire (Extended Data Fig. 10f) with an elevated proportion of shorter CDR3 length (Extended Data Fig. 10g,h) when compared to HCs, whereas TCR-V $\beta$  gene usage was preserved (Extended Data Fig. 10i). Of note, the same alterations were observed in

the TCR-V $\beta$  repertoire of the pRD T<sub>reg</sub> cells (Extended Data Fig. 10j-m).

By assessing inflammatory and T<sub>FH</sub> cell-specific cytokine-producing capacity of T<sub>H</sub> cells in vitro we found elevated IFN- $\gamma$ , TNF- $\alpha$  and IL-21 production in the patients (Fig. 8g,h). To determine whether increased cytokine production of total T<sub>H</sub> cells merely results from the abundant presence of effector cells (cT<sub>FH</sub> and memory) in pRD or whether these cells indeed possess elevated cytokine-producing capacity, we measured cytokine production on presorted T<sub>H</sub> populations. Notably, IFN- $\gamma$  and TNF- $\alpha$  production of effector T<sub>H</sub> cells (cT<sub>FH</sub> and memory) was comparable to those of HCs (Fig. 8i,j). Elevated IFN- $\gamma$  and TNF- $\alpha$  production of naive T<sub>H</sub> cells observed in pRD may reflect the inclusion of

early effector-committed cells. In contrast, IL-21 production was found to be significantly elevated in the  $cT_{FH}$  and memory cells of patients with pRD, indicating their potential role in B cell activation (Fig. 8i,j). Indeed, by assessing resting mature naive B cell-activating capacity of sorted  $cT_{FH}$  cells (Extended Data Fig. 10n and Fig. 8k), we found that pRD  $cT_{FH}$  cells induced more robust B cell activation than those of HCs, as reflected by increased presence of plasma cells in the culture (Fig. 8l,m). Hence, pRD is associated with elevated frequencies of hyperactivated  $T_H$  and  $cT_{FH}$  cells that may promote the breach in B cell tolerance and the expansion of autoreactive B cells and may contribute the induction of T-bet<sup>+</sup> B cells in pRD as demonstrated recently<sup>39</sup>.

## Discussion

Our central finding on B cells obtained from a large cohort of patients with pRD includes that (1) the formation of the primary immunoglobulin repertoire is severely restricted; (2) both the central and peripheral tolerance filters are impaired, allowing the accumulation of poly/autoreactive B cells in the primary immunoglobulin repertoire; and (3) nascent B cells undergo rapid activation, expansion and somatic diversification; and clonally related descendants persist and accumulate in the effector repertoires. Together, these events render the antibody repertoire of patients with pRD defective in their ability to efficiently clear foreign antigens but maintain reactivity to self.


First, we revealed severe diversity restriction with increased clonality in the primary repertoire and impaired somatic diversification in the effector compartment in pRD. A previous assessment of the repertoire of total B cells from peripheral blood of patients with pRD-CID demonstrated preserved diversity and proper somatic diversification<sup>14</sup>. The contradiction between the two studies is most likely based on the different approaches. Lee et al. performed analysis on total blood representing B cell subsets by their *in vivo* distribution, reflecting on mainly memory cells given their predominance over naive cells in pRD. Therefore, diversity, CSR and SHM could be seemingly normal, but features of the primary repertoire remains blurred. In contrast, by investigating B cell subsets separately, we documented restricted primary BCR repertoire with early CSR/SHM along with impaired somatic diversification in memory cells. These repertoire abnormalities accumulate in insufficient production of protective high affinity antibodies and inadequate humoral immune response in pRD. Indeed, impaired clearance of foreign antigens is demonstrated by persisting viral load, recurrent chronic infections<sup>4</sup> and likely microbiota translocation due to intestinal inflammation and defective microbiota containment<sup>40</sup>. Hence, compromised adaptive immunity in pRD leads to the accumulation of foreign and/or microbiota-derived antigens, pathogen and damage-associated molecular pattern (PAMP/DAMP) molecules, exposing the immune system to persistent and abundant antigen load.

The second part of our findings delineated B cell tolerance impairments in pRD. Although, the role of *RAG1/RAG2* genes in receptor editing has been established<sup>7,8</sup>, our study quantitatively reports defective central tolerance in pRD. We also identified the peripheral tolerance impaired in all individuals with pRD investigated, implying an indirect role of the *RAG1/RAG2* genes in the process. Furthermore, patients with pRD-Ag accumulated more polyreactive B cells than the asymptomatic pRD-N infant, demonstrating the plasticity of peripheral tolerance and how it may worsen with age in pRD.

Regarding peripheral tolerance, plasma BAFF level seems to act as a major checkpoint, given that its excess rescues autoreactive B cells and promotes autoimmunity<sup>41–43</sup>. The high plasma BAFF level is likely resulted from B cell lymphopenia and inflammation in pRD. Progressive B cell lymphopenia in pRD is a direct consequence of impaired RAG function and may worsen with age<sup>44</sup>. In addition, BAFF expression further increases in the presence of type I IFNs, IFN- $\gamma$ , IL-10 and granulocyte colony-stimulating factor (G-CSF) as well as by the activation of TLRs<sup>45</sup>. Therefore, chronic inflammation secondarily to impaired RAG function is likely an additional trigger to impair peripheral tolerance through BAFF. In addition, *RAG1/RAG2* genes play critical roles in the development<sup>46</sup>, repertoire and proper function of  $T_{reg}$  cells<sup>38</sup>, a key factor of peripheral B cell tolerance<sup>37</sup>. Hence, impaired  $T_{reg}$  cells also represent a defective peripheral B cell tolerance checkpoint in pRD. In addition, abnormal  $T_{FH}$  cell function may also contribute to the selection and affinity maturation of specific, high affinity class-switched autoantibody-producing B cells such as those targeting cytokines<sup>5</sup>. As pRD is associated with the expansion and overactivation of  $cT_{FH}$  cells it may contribute to the humoral autoimmunity beyond B cell-intrinsic components. These findings imply that targeted anti-BAFF, CTLA4-Ig and/or  $T_{FH}$  therapies may represent options for treatment of clinical autoimmune diseases in pRD.

The third component of our findings identified widespread promiscuous B cell activation that is likely the direct consequence of the two aforementioned phenomena. While in steady state, the population size of the antigen-specific B cells for any particular antigen is very small, a repertoire enriched for polyreactive clones allows for widespread antigen recognition and capture. Indeed, we have demonstrated that antibodies cloned from B cells (a surrogate of their BCRs) recognize a broad variety of antigens (such as DNA, protein and LPS) in pRD. Hence, nascent B cells expressing polyreactive BCRs are likely constantly exposed to PAMPs/DAMPs, which they can capture, internalize and deliver to TLRs. Co-signaling through BCRs and TLRs can synergistically trigger and sustain polyreactive B cell hyperactivation<sup>47–49</sup>. In addition, the inflammatory milieu secondary to impaired antigen clearance can also facilitate B cell activation by an antigen-independent manner via both the canonical and the non-canonical NF- $\kappa$ B pathways. In addition, widespread

**Fig. 8 | Characterization of  $T_H$  cells.** **a**, Gating for  $T_{reg}$ ,  $cT_{FH}$ , CXCR5<sup>-</sup> memory and naive  $T_H$  cells.  $T_H$  subsets are shown from a live lymphocyte CD4<sup>+</sup> gate in representative HC-Ag and a patient with pRD-Ag. **b**, Frequencies of  $T_H$  subsets. **c**, PD-1<sup>+</sup>ICOS<sup>+</sup> cells in  $T_H$  subsets. Overlaid plots show PD-1<sup>+</sup>ICOS<sup>+</sup> cells by subsets in a representative HC-Ag and an individual with pRD-Ag. **d**, Proportion of PD-1<sup>+</sup>ICOS<sup>+</sup>  $T_H$  cells. Graphs show frequencies of PD-1<sup>+</sup>ICOS<sup>+</sup> cells in total  $T_H$  cells and by subsets. **e**, Correlation of PD-1 and CCR7 expression. Fraction of CCR7<sup>+</sup>PD-1<sup>+</sup>, CCR7<sup>+</sup>PD-1<sup>-</sup>, CCR7<sup>-</sup>PD-1<sup>-</sup> and CCR7<sup>-</sup>PD-1<sup>+</sup> are shown in CXCR5<sup>-</sup> memory and  $cT_{FH}$  cells in a representative HC-Ag and a patient with pRD-Ag. **f**, CXCR5<sup>-</sup> memory and  $cT_{FH}$  populations fractioned by PD-1 and CCR7 expression. Data for **b,d,f** are shown as mean  $\pm$  s.e.m. with individual values from HC-N ( $n=1$ ), HC-Ags ( $n=10$ ), pRD-N ( $n=1$ ) and pRD-Ags ( $n=8$ ). **g**, *In vitro* IFN- $\gamma$ , TNF- $\alpha$  and IL-21 production by total  $T_H$  cells. Data are shown as overlaid histogram plots depicting a representative stimulated individual with HC-Ag and a patient with pRD-Ag; and an unstimulated HC-Ag from live lymphocyte CD4<sup>+</sup> gate. **h**, Frequencies of IFN- $\gamma$ , TNF- $\alpha$  and IL-21 positive  $T_H$  cells. **i**, *In vitro* IFN- $\gamma$ , TNF- $\alpha$  and IL-21 production by  $T_H$  subsets. Data are shown as in **g** by  $T_H$  subsets. **j**, Frequency of IFN- $\gamma$ , TNF- $\alpha$  and IL-21 positive cells by  $T_H$  subsets. Data for **h** and **j** are shown as mean  $\pm$  s.e.m. with individual values from HC-Ags ( $n=7$ ) and pRD-Ags ( $n=4$ ). Data for **g–j** were obtained from four independent experiments. For statistical analysis Mann-Whitney *U*-test with Holm-Šidák multiple comparison were performed for **b** and two-sided unpaired Student's *t*-test for **d,f,h,j** to compare HC-Ag and pRD-Ag. **k**, Approach to assess  $cT_{FH}$  function. **l**, Detection of PCs. PCs were identified from the live lymphocyte gate in a representative HC-Ag and an individual with pRD-Ag. **m**, Proportion of PCs in culture. PC frequencies induced by HC-Ag ( $n=4$ ) or pRD-Ag ( $n=4$ ).  $cT_{FH}$  cells are shown as individual values and statistical analyses were performed using two-sided paired Student's *t*-test. Data for **l,m** were obtained from four independent experiments.



bystander  $T_H$  cell interactions may also serve as a potential driver, given that  $T_{FH}$  cells from patients had elevated capacity to induce B cell activation *in vitro*.

We propose that the combination of widespread B cell activation with progressive B cell lymphopenia creates a distinct immune phenotype in pRD. The premature activation of nascent B cells accelerates their development, rapidly bypassing early stages as indicated by the shrinking size of transitional and resting mature naive compartments, similarly as seen in a single case of a patient with pRD<sup>50</sup> and also in severe SARS-CoV-2 infections<sup>51</sup>. Activation is also illustrated by the expansion of activated naive and other IgD<sup>+</sup>CD27<sup>-</sup>CD38<sup>-</sup> naive subsets along with NSM compartments. These alterations seem to be a unique feature of pRD compared to other primary immune regulatory disorders and may serve as a biomarker for pRD. It also raises the question as to whether patients with pRD would benefit from monitoring and targeting persistent antigen load (such as virus infection and translocated microbiota) to predict and prevent widespread B cell activation that may escalate to clinical autoimmunity.

Another consequence of the widespread activation is reflected by the unusual early somatic diversification of the immunoglobulin loci, indicating exposure to antigens and/or cytokines that trigger AID activity<sup>52,53</sup>. SHM and CSR are the gold standards for distinguishing antigen-experienced B cells from naive cells and trump gating based on surface markers. Thus, although the CD38<sup>int</sup> subset phenotypically represented resting mature naive B cells in pRD, at least a fraction of them cannot be considered bone fide naive cells. A similar phenomenon has been described in systemic lupus erythematosus, where altered chromatin accessibility and gene expression profile with AID induction were identified in phenotypically naive B cells<sup>54,55</sup>. This suggests that dysregulation of surface marker expression may occur frequently under pathological conditions and, therefore, does not accurately distinguish antigen-naive and antigen-experienced B cells.

Nevertheless, we found that widespread B cell activation is associated with a unique B cell fate and somatic diversification in pRD. Analyzing the trajectories of individual B cell clones in distinct repertoires of patients with pRD, we identified persisting polyreactive and non-polyreactive B cell clones with intercompartmental clonal connections, which undergo stochastic somatic diversification and acquire strong positive antigenic selection in selected cases. This may explain the presence of high affinity class-switched autoantibodies, such as those targeting IFN- $\alpha$ .

Activation of B cells with polyreactive BCRs recognizing highly repetitive motifs may drive these cells toward extrafollicular destiny. Indeed, CXCR5<sup>lo</sup>CD11c<sup>hi</sup>T-bet<sup>+</sup> autoimmune-prone ABCs, with potential extrafollicular origin<sup>34,56,57</sup>, are expanded in pRD. These cells may stem from exaggerated TLR engagement due to the chronic exposure to pathogens from recurrent infections<sup>33,57–59</sup>. ABCs in mouse models or human diseases has been associated with humoral autoimmunity<sup>33,56,58</sup>, hence, shifting B cell maturation toward ABC fate provides an additional aspect of tolerance defect. In addition, dominance of potential extrafollicular B cell fate over the germinal center (GC) results in less efficient antibody affinity maturation and CSR rendering antigen clearance and microbiota containment impaired; and exaggerating immune dysregulation. Indeed, although the memory compartment is expanded, its impaired SHM and CSR indicates improper affinity maturation. Finally, activated memory B cells with increased HLA-DR expression and ABC fate may attain the ability to present antigens to naive T cells with high efficiency as professional antigen presenting cells in a TLR-dependent manner<sup>57</sup>. Hence, dysregulated B cells may contribute to T cell dysregulation and  $T_{FH}$  cell expansion in pRD.

In summary, our findings support the concept that adequate RAG function during early B cell development is critical to establish functional B cell tolerance and govern normal B cell development in

the periphery. We demonstrated that impaired RAG function results in restricted primary B cell repertoire and impaired tolerance. Together these two events lead to inefficient humoral immunity with persistent antigenic load and a mature naive B cell pool enriched with polyreactive clones. On this ground, environmental triggers (such as chronic infections and microbiota translocation) along with intrinsic factors (such as elevated BAFF, reduced  $T_{reg}/T_{FH}$  cell ratio and inflammatory cytokine milieu) gradually provoke profound B cell dysregulation with time that includes widespread B cell activation, developmental skewing, accumulation of T-bet<sup>+</sup> cells and expansion of autoreactive clones. Therefore, our study demonstrates roles of *RAG1/RAG2* genes in regulating tolerance and governing B cell fate in the periphery that points beyond their well-understood role in V(D)J recombination and receptor editing.

### Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41590-022-01271-6>.

Received: 10 June 2021; Accepted: 16 June 2022;

Published online: 28 July 2022

### References

- Oettinger, M. A., Schatz, D. G., Gorka, C. & Baltimore, D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. *Science* **248**, 1517–1523 (1990).
- Lee, Y. N. et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. *J. Allergy Clin. Immunol.* **133**, 1099–1108 (2014).
- Lawless, D. et al. Prevalence and clinical challenges among adults with primary immunodeficiency and recombination-activating gene deficiency. *J. Allergy Clin. Immunol.* **141**, 2303–2306 (2018).
- Notarangelo, L. D., Kim, M. S., Walter, J. E. & Lee, Y. N. Human RAG mutations: biochemistry and clinical implications. *Nat. Rev. Immunol.* **16**, 234–246 (2016).
- Walter, J. E. et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. *J. Clin. Invest.* **125**, 4135–4148 (2015).
- Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. *Science* **301**, 1374–1377 (2003).
- Nemazee, D. Mechanisms of central tolerance for B cells. *Nat. Rev. Immunol.* **17**, 281–294 (2017).
- Tiegs, S. L., Russell, D. M. & Nemazee, D. Receptor editing in self-reactive bone marrow B cells. *J. Exp. Med.* **177**, 1009–1020 (1993).
- Romberg, N. et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. *J. Clin. Invest.* **123**, 4283–4293 (2013).
- Walter, J. E. et al. Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. *J. Exp. Med.* **207**, 1541–1554 (2010).
- Cassani, B. et al. Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. *J. Exp. Med.* **207**, 1525–1540 (2010).
- Schuetz, C. et al. An immunodeficiency disease with RAG mutations and granulomas. *N. Engl. J. Med.* **358**, 2030–2038 (2008).
- Henderson, L. A. et al. Expanding the spectrum of recombination-activating gene 1 deficiency: A family with early-onset autoimmunity. *J. Allergy Clin. Immunol.* **132**, 969–971 (2013).
- Lee, Y. N. et al. Characterization of T and B cell repertoire diversity in patients with RAG deficiency. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.aah6109> (2016).
- Schuetz, C. et al. Lesson from hypomorphic recombination-activating gene (RAG) mutations: why asymptomatic siblings should also be tested. *J. Allergy Clin. Immunol.* **133**, 1211–1215 (2014).
- Ijspeert, H. et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. *J. Allergy Clin. Immunol.* **133**, 1124–1133 (2014).
- Wu, K. Y. et al. Arthritis in two patients with partial recombination activating gene deficiency. *Front. Pediatr.* **7**, 235 (2019).
- Dalal, I. et al. Evolution of a T-B- SCID into an Omenn syndrome phenotype following parainfluenza 3 virus infection. *Clin. Immunol.* **115**, 70–73 (2005).



19. Ehl, S. et al. A variant of SCID with specific immune responses and predominance of  $\gamma\delta$  T cells. *J. Clin. Invest.* **115**, 3140–3148 (2005).
20. Goda, V. et al. Partial RAG deficiency in a patient with varicella infection, autoimmune cytopenia, and anticytokine antibodies. *J. Allergy Clin. Immunol. Pr.* **6**, 1769–1771 (2018).
21. Chitty-Lopez, M. et al. Asymptomatic infant with atypical SCID and novel hypomorphic RAG variant identified by newborn screening: a diagnostic and treatment dilemma. *Front. Immunol.* **11**, 1954 (2020).
22. Farmer, J. R. et al. Outcomes and treatment strategies for autoimmunity and hyperinflammation in patients with RAG deficiency. *J. Allergy Clin. Immunol. Pr.* **7**, 1970–1985 (2019).
23. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
24. Shearer, W. T. et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *J. Allergy Clin. Immunol.* **112**, 973–980 (2003).
25. Dorna, M. B. et al. Combined immunodeficiency with late-onset progressive hypogammaglobulinemia and normal B cell count in a patient with RAG2 deficiency. *Front. Pediatr.* **7**, 122 (2019).
26. Geier, C. B. et al. Vasculitis as a major morbidity factor in patients with partial RAG deficiency. *Front. Immunol.* **11**, 574738 (2020).
27. Pascual, V. et al. Nucleotide sequence analysis of the V regions of two IgM cold agglutinins. Evidence that the VH4-21 gene segment is responsible for the major cross-reactive idiotype. *J. Immunol.* **146**, 4385–4391 (1991).
28. Sanz, I. et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. *Front. Immunol.* **10**, 2458 (2019).
29. Tipton, C. M. et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. *Nat. Immunol.* **16**, 755–765 (2015).
30. Jenks, S. A. et al. Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. *Immunity* **49**, 725–739 (2018).
31. Masilamani, M., Kassahn, D., Mikkat, S., Glocker, M. O. & Illges, H. B cell activation leads to shedding of complement receptor type II (CR2/CD21). *Eur. J. Immunol.* **33**, 2391–2397 (2003).
32. Warnatz, K. et al. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. *Immunobiology* **206**, 502–513 (2002).
33. Cancro, M. P. Age-associated B cells. *Annu. Rev. Immunol.* **38**, 315–340 (2020).
34. Rubtsova, K., Rubtsov, A. V., van Dyk, L. F., Kappler, J. W. & Marrack, P. T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance. *Proc. Natl Acad. Sci. USA* **110**, E3216–E3224 (2013).
35. Neven, B. et al. Cutaneous and visceral chronic granulomatous disease triggered by a rubella virus vaccine strain in children with primary immunodeficiencies. *Clin. Infect. Dis.* **64**, 83–86 (2017).
36. Furudoi, A. et al. Spleen histologic appearance in common variable immunodeficiency: analysis of 17 cases. *Am. J. Surg. Pathol.* **40**, 958–967 (2016).
37. Kinnunen, T. et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. *Blood* **121**, 1595–1603 (2013).
38. Rowe, J. H. et al. Abnormalities of T-cell receptor repertoire in CD4(+) regulatory and conventional T cells in patients with RAG mutations: implications for autoimmunity. *J. Allergy Clin. Immunol.* **140**, 1739–1743 e1737 (2017).
39. Keller, B. et al. The expansion of human T-bet(high)CD21(low) B cells is T cell dependent. *Sci. Immunol.* **6**, eabh0891 (2021).
40. Rigoni, R. et al. Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects. *J. Exp. Med.* **213**, 355–375 (2016).
41. Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. *Immunity* **20**, 441–453 (2004).
42. Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. *Immunity* **20**, 785–798 (2004).
43. Meffre, E. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. *Ann. NY Acad. Sci.* **1246**, 1–10 (2011).
44. Labrie, J. E. 3rd, Sah, A. P., Allman, D. M., Cancro, M. P. & Gerstein, R. M. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. *J. Exp. Med.* **200**, 411–423 (2004).
45. Mackay, F. & Schneider, P. Cracking the BAFF code. *Nat. Rev. Immunol.* **9**, 491–502 (2009).
46. Poliani, P. L. et al. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. *Blood* **114**, 105–108 (2009).
47. Bernasconi, N. L., Onai, N. & Lanzavecchia, A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. *Blood* **101**, 4500–4504 (2003).
48. Ruprecht, C. R. & Lanzavecchia, A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. *Eur. J. Immunol.* **36**, 810–816 (2006).
49. Giltiay, N. V. et al. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. *J. Exp. Med.* **210**, 2773–2789 (2013).
50. Qing, M. et al. RAG1 splicing mutation causes enhanced B cell differentiation and autoantibody production. *JCI Insight* **6**, e148887 (2021).
51. Kaneko, N. et al. Loss of Bcl-6-expressing T follicular helper. *Cells Germlinal Cent. COVID-19. Cell* **183**, 143–157 (2020).
52. He, B., Qiao, X. & Cerutti, A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. *J. Immunol.* **173**, 4479–4491 (2004).
53. Litinskiy, M. B. et al. DCs induce CD40-independent immunoglobulin class switching through BlyS and APRIL. *Nat. Immunol.* **3**, 822–829 (2002).
54. Schärer, C. D. et al. Epigenetic programming underpins B cell dysfunction in human SLE. *Nat. Immunol.* **20**, 1071–1082 (2019).
55. Schärer, C. D. et al. ATAC-seq on biobanked specimens defines a unique chromatin accessibility structure in naive SLE B cells. *Sci. Rep.* **6**, 27030 (2016).
56. Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E. & Sanz, I. Extrafollicular responses in humans and SLE. *Immunol. Rev.* **288**, 136–148 (2019).
57. Rubtsov, A. V. et al. CD11c-expressing B cells are located at the T cell/B cell border in spleen and are potent APCs. *J. Immunol.* **195**, 71–79 (2015).
58. Rubtsov, A. V. et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. *Blood* **118**, 1305–1315 (2011).
59. Naradikian, M. S. et al. Cutting edge: IL-4, IL-21, and IFN- $\gamma$  interact to govern T-bet and CD11c expression in TLR-activated B cells. *J. Immunol.* **197**, 1023–1028 (2016).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

<sup>1</sup>Division of Pediatric Allergy/Immunology, University of South Florida at Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. <sup>2</sup>Department of Pediatrics, University of Szeged, Szeged, Hungary. <sup>3</sup>Cancer and Blood Disorders Institute and Department of Surgery, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. <sup>4</sup>Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. <sup>5</sup>Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, USA. <sup>6</sup>Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA. <sup>7</sup>Department of Pathology & Laboratory Medicine, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA. <sup>8</sup>Eurofins Viracor Laboratories, Lee Summit, MO, USA. <sup>9</sup>Immunology Outpatient Clinic, Vienna, Austria. <sup>10</sup>Belarusian Research Center for Pediatric Oncology, Minsk, Belarus. <sup>11</sup>Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. <sup>12</sup>Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait. <sup>13</sup>Department of Pediatrics, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil. <sup>14</sup>Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA. <sup>15</sup>Childhood Leukemia Investigation Prague, Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. <sup>16</sup>Allergy Immunology Division, Department of

Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. <sup>17</sup>Institute for Immunology, the University of Pennsylvania, Philadelphia, PA, USA. <sup>18</sup>Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University, Stanford, CA, USA. <sup>19</sup>Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands. <sup>20</sup>Department of Clinical Immunology, University Hospital Alexandrovska, Medical University, Sofia, Bulgaria. <sup>21</sup>Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czech Republic. <sup>22</sup>Université de Paris, Paris, France. <sup>23</sup>Pediatric Hematology-Immunology and Rheumatology Unit, Necker-Enfants Malades Université Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. <sup>24</sup>Laboratory of Genome Dynamics in the Immune System, INSERM UMR1163, Institut Imagine, Paris, France. <sup>25</sup>Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR1163, Institut Imagine, Paris, France. <sup>26</sup>Windom Allergy, Asthma and Sinus, Sarasota, FL, USA. <sup>27</sup>Department of Immunology and Allergy, Sheffield Teaching Hospitals, Sheffield, UK. <sup>28</sup>Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, UK. <sup>29</sup>National Institute for Health Research-Leeds Musculoskeletal Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, St James's University Hospital, Leeds, UK. <sup>30</sup>Division of Allergy, Immunology and Pulmonary Medicine, Duke University School of Medicine, Durham, NC, USA. <sup>31</sup>Cancer and Blood Disorder Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. <sup>32</sup>Division of Allergy and Immunology, Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, VA, USA. <sup>33</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. <sup>34</sup>Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics and Jeffrey Modell Diagnostic and Research Center, University of California, Los Angeles, Los Angeles, CA, USA. <sup>35</sup>Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA. <sup>36</sup>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. <sup>37</sup>Department of Immunobiology, Yale University, New Haven, CT, USA. <sup>38</sup>Section of Rheumatology, Allergy and Clinical Immunology, Yale School of Medicine, New Haven, CT, USA. <sup>39</sup>Division of Allergy and Immunology, Massachusetts General Hospital for Children, Boston, MA, USA.

✉e-mail: [kcsomos@usf.edu](mailto:kcsomos@usf.edu); [janwalter@usf.edu](mailto:janwalter@usf.edu)

## Methods

**Human samples.** Sixteen patients with pRD and 27 healthy individuals were enrolled in this study. All were recruited according to protocols approved by local Institutional Review Boards (IRBs) as follows: USF-Pro00035468 (PI, J.E.W.), USF-Pro00025693 (PI, J.E.W.), JHMI-IRB00175372 (PI, J.E.W.), JHMI-IRB00097062 (PI, J.W.L.) and JHMI-IRB00097938 (PI, J.W.L.). Inclusion criteria for patients with pRD were carrying confirmed hypomorphic homozygous or compound heterozygous *RAG1/RAG2* mutations and displaying CID or CID-G/AI phenotype. Exclusion criteria for HCs were symptoms of cold, temperature above 37.8°C and being treated with antibiotics or antivirals in the past 2 weeks. All protocols followed local ethics recommendations and informed consent was obtained. No compensation was provided. Peripheral blood samples from individuals with pRD and HCs were obtained via standard phlebotomy using Na-Hep or EDTA blood collection tubes and processed or frozen within 48 h. Paraffin-embedded spleen tissue blocks from P5 and an aged-matched HC were provided by B.N. and H.L.M., respectively.

**Autoantibody, anticytokine antibody and unmutated VH4-34 (9G4) antibody detection.** Autoantibodies to protein antigens from plasma samples were detected with standard in-house developed ELISAs. Briefly, 96- or 384-well ELISA plates (MaxiSorp; Thermo Fisher Scientific) were coated with 1 or 2 µg ml<sup>-1</sup> recombinant human proteins or 10 µg ml<sup>-1</sup> human embryonic kidney 293 cell (HEK293) protein extract representing broad cellular autoantigen mixture in PBS by incubation overnight at 4°C. Recombinant antigens were purchased from Surmodics (human M2 antigen, intrinsic factor, proliferating cell nuclear antigen, threonyl-tRNA synthetase, Ro/SSA-52 Kda, thyroid peroxidase, U1-SnRNP C protein, thyroglobulin and ribosomal phosphoprotein P0), BioLegend (IFN-α) or Thermo Fisher Scientific (IL-12 and IFN-ω). Human recombinant tissue transglutaminase protein was kindly gifted by L. Fesus (University of Debrecen). To detect anti-DNA antibodies, plates were coated with 10 µg ml<sup>-1</sup> DNA (Sigma-Aldrich) in PBS. Plates were then washed in PBS-Tween 0.05%, blocked by incubation with the same buffer supplemented with 2% BSA, washed and then incubated with 1:100, 1:200, 1:400 and 1:800 dilutions of plasma samples from patients or controls for 2 h at room temperature. Plates were thoroughly washed and then incubated with HRP-conjugated Fc-specific polyclonal goat anti-human IgG Ab (Sigma-Aldrich) for 1 h at room temperature. After washing, HRP substrate was added (TMB; Thermo Fisher Scientific), the reaction was terminated with sulfuric acid (Sigma-Aldrich) and absorbance was measured at 450 nm in an ELISA reader. Results are expressed as the blank corrected absorbances and z scores (corrected absorbance minus mean of HCs divided by s.d. of the HC values). Unmutated VH4-34 (9G4) IgM antibody was detected by coating the ELISA plate with 9G4-purified rat anti-idiotypic antibody (IGM Biosciences) and using HRP-conjugated Fc-specific polyclonal goat anti-human IgM antibody (Thermo Fisher Scientific).

**Cytokine, endotoxin, soluble IL-2 receptor and virus (EBV and CMV) quantification from plasma.** IFN-γ, IL-10, BAFF (R&D Systems) and endotoxin (Lifespan Bioscience) plasma concentrations were measured using ELISAs. sIL-2R plasma level was measured by Luminex assay (Thermo Fisher Scientific). EBV and CMV virus titers were determined by Viracor Eurofins.

**Cell preparation, flow cytometry and cell sorting.** Peripheral blood mononuclear cells were isolated from peripheral blood samples by using Ficoll-Paque PLUS density gradient centrifugation (GE Healthcare Life Sciences). B cells were enriched with positive magnetic separation using anti-CD20 magnetic beads (Miltenyi Biotec). Cells were stained with live–dead discriminator (Fixable Viability Dye eFluor 780, Thermo Fisher Scientific), Fc receptors were blocked using Human TruStain FcX (BioLegend) and then surface antibody stained. When appropriate, surface-stained cells were fixed, permeabilized and followed by intracellular staining. Cells were analyzed and/or sorted with a FACSAria II (BD Bioscience) using FACSDiva software v.10. Fluorescence-activated cell sorting data were visualized with FlowJo software v.10.7.1 (TreeStar) and, when indicated, further analyzed by FlowSOM (v.2.5), DownSample (v.3.0), *t*-SNE (v.2.0) and HyperFinder (v.0.6.2) FlowJo plugins.

**Unsupervised high-dimensional clustering for B cell subset identification and quantification.** Unsupervised high-dimensional analysis was performed using FlowSOM plugin<sup>60</sup> to achieve objective B cell subset identification and quantification from the patients with pRD. Briefly, flow cytometry data obtained from four patients (P9, P12, P14 and P16) and four age-appropriate HCs (C1, C3, C5 and C7) (inclusion criteria of data were having at least 5,000 live CD19<sup>+</sup> cells and acquisition performed with identical flow cytometry panel) for CD21, CD24, CD27, CD38, IgD and IgM parameters were simultaneously used. First, full datasets were randomly downsampled to 5,000 live CD19<sup>+</sup> cells from each donor using DownSample FlowJo plugin. Next donors were concatenated and then each cell of the generated B cell pool was assigned by a self-organizing map in a 10 × 10 grid, resulting 100 different nodes. Then, minimal spanning trees (MSPs) were built from the nodes in each donor to visualize similar nodes in branches and their relative connection to each other (Extended Data Fig. 3a). To identify B

cell populations, nodes were classified into metaclusters that revealed 16 different metaclusters each representing a unique B cell subset (Extended Data Fig. 3b). To associate these metaclusters to B cell subsets, first, the mean values of each marker (Extended Data Fig. 3c) were min–max normalized in each metacluster for all donors to rescale value range of 0–1. Next, the means of each value were calculated and value ranges for the expression of each marker were defined as 0–0.1, 0.1–0.3, 0.3–0.7, 0.7–0.9 and 0.9–1.0 corresponding to ‘negative’, ‘low’, ‘intermediate’, ‘positive’ and ‘high’ expression levels, respectively (Extended Data Fig. 3d). In the last step, each metacluster was assigned to a unique B cell subset based on the expression pattern of the six markers and the current advances of human B cell immunophenotyping<sup>28</sup>. Relative frequencies of each subset by donors were also obtained from the FlowSOM analysis (Extended Data Fig. 3e).

***t*-distributed stochastic neighbor embedding.** A *t*-SNE algorithm was used for visualizing the multidimensional flow dataset in a dimension-reduced data space to compare B cell subset distribution in pRD compared to HCs. *t*-SNE analysis was performed on the concatenated dataset defined in the FlowSOM analysis with the same parameters (CD21, CD24, CD27, CD38, IgD and IgM) using default settings.

**Establishing two-dimensional sequential gating strategy for B cell subset identification using HyperFinder.** To extend immunophenotyping to the entire patient cohort a two-dimensional sequential gating was constructed using HyperFinder FlowJo plugin. Briefly, HyperFinder was applied on the concatenated dataset defined in the FlowSOM analysis with the same parameters (CD21, CD24, CD27, CD38, IgD and IgM) for searching all combinations of available parameters to find a two-dimensional convex polygon gating strategy that most accurately distinguishes the target B cell subset from the background B cell populations. Optimal sequential gateings for each of the 16 target B cell subsets were automatically calculated by maximizing Fm-score. This approach accurately recapitulated FlowSOM analysis on the test dataset (P9, P12, P14, P16, C1, C3, C5 and C7) as demonstrated with high F-measures for each B cell subset (0.84 ± 0.06 mean ± s.d., range 0.68–0.96). Therefore, the constructed sequential gateings were utilized on the patients with pRD (14 pRD-Ag and one pRD-N) along with 20 HCs (16 HC-Ag and 4 HC-N) to evaluate their immunophenotype (Extended Data Fig. 3f).

**Immunohistochemistry.** Immunohistochemistry was performed using anti-CD20 (L26 mouse monoclonal primary antibody, Roche Diagnostics, 0.3 µg ml<sup>-1</sup>), anti-CD21 (2G9 mouse monoclonal primary antibody, Cell Marque Tissue Diagnostics, 0.5 µg ml<sup>-1</sup>), anti-CD4 (SP35 rabbit monoclonal primary antibody, Roche Diagnostics, 2.5 µg ml<sup>-1</sup>) and anti-BCL2 (I24 mouse monoclonal primary antibody, Roche Diagnostics, 2.62 µg ml<sup>-1</sup>) antibodies on a Leica DM LB2 clinical brightfield microscope.

**Multicolor immunofluorescence staining.** Human spleen samples were fixed in formalin, embedded in paraffin and sectioned at 5 µm. After deparaffinization, antigen retrieval was performed to unmask the antigenic epitope with 1 × Tris-EDTA, pH 8.5, buffer (Sigma-Aldrich E1161) in a deoclocking chamber (Biocare Medical). Sections were blocked for 1 h at room temperature with TBS (0.025% Triton X-100, 1% BSA and 0.3 M glycine), then incubated with the following monoclonal antibodies at 1:100 dilution in TBS (0.025% Triton X-100 and 1% BSA) overnight at 4°C: anti-CD19 antibody coupled to AlexaFluor488 (ab196468, Abcam); anti-CD4 antibody coupled to AlexaFluor555 (ab280849, Abcam); anti-T-bet antibody coupled to AlexaFluor647 (ab225198, Abcam); or anti-PD-1 antibody coupled to AlexaFluor647 (ab201825, Abcam). The samples were then mounted with Fluoromount-G (0100-01 Southern Biotech) and imaged under a confocal microscope with a resonant scanning disk (Nikon A1R, Nikon Instruments) with Z-sectioning (0.5 µm), using Nikon NIS-Elements AR Analysis 4.40 software.

**Indirect fluorescent antibody assay.** For the detection of autoantibodies against cellular antigens, we performed IFA on HEp-2 slides (human epithelial cells, Bio-Rad) following the manufacturer's instructions. Briefly, plasma samples (25 µl) were added to the substrate for 20 min. Then, substrates were rinsed with PBS for 10 min and incubated with 25 µl fluorescein-conjugated (FITC) antiserum for 20 min at room temperature. Slides were then washed with PBS and counterstained with Evans blue dye in PBS for 10 min first and with DAPI for additional 10 min. The slides were finally washed in PBS, drained and mounted with coverslip. For optimal visualization of the topographic distribution of the immunofluorescence (pattern) and quantification (titer) of the autoantibodies present in the plasma samples, confocal microscopy was performed. Nuclear binding of autoantibodies was determined from three-dimensional reconstructed confocal images as a fraction of the sum of fluorescence intensity contained in the DAPI-positive area by total DAPI-positive area per field. Cytoplasmic binding was quantified as the fraction of the sum of fluorescence intensity in Evans blue-positive area by total Evans blue-positive area per field. Eight high-resolution confocal images per sample (×60 lenses; 1,024 × 1,024 pixels; Nikon A1R; Nikon Instruments) with thin Z-sectioning (0.1 µm) were captured and analyzed with Nikon NIS-Elements AR Analysis 5.21 software. Evaluation of the staining pattern (nucleus, homogenous,

rim, speckled, nucleolar and spindle; cytoplasm, mitochondrial and smooth muscle) and fluorescent intensity grade (+4, brilliant apple green; +3, bright apple green; +2, clearly distinguishable positive; +1, lowest specific distinguishable from background and 0, negative) was performed according to the manufacturer's instructions.

**In vitro cell cultures.** For the naive B cell differentiation assay,  $5 \times 10^4$  sorted resting naive B cells (CD19<sup>+</sup>CD27<sup>-</sup>IgD<sup>+</sup>CD24<sup>int</sup>CD38<sup>int</sup>IgM<sup>+</sup>) (purity >98%) were seeded in a 96-well culture plate in lymphocyte medium (RPMI 1640 complete medium (100  $\mu$ l per well) supplemented with 10% heat-inactivated fetal bovine serum and activated with CpG ODN 2006 (400  $\mu$ g ml<sup>-1</sup>; InvivoGen), recombinant human CD40L (1  $\mu$ g ml<sup>-1</sup>; R&D Systems) and recombinant human IL-21 (50 ng ml<sup>-1</sup>; BioLegend). After 7 d cells were stained and analyzed for memory B cells (live CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>low-int</sup>) and plasma cells (live CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>hi</sup>) by flow cytometry.

For activation of naive B cells with human plasma,  $5 \times 10^4$  sorted resting naive B cells (CD19<sup>+</sup>CD27<sup>-</sup>IgD<sup>+</sup>CD24<sup>int</sup>CD38<sup>int</sup>IgM<sup>+</sup>) (purity >98%) from an HC were cultured in vitro in 96-well culture plate in 100  $\mu$ l per well complete RPMI 1640 or ImmunoCult Human B Cell Expansion medium (StemCell) supplemented with recombinant human IL-21 (10 ng ml<sup>-1</sup>; BioLegend) and either plasma from a patient with pRD or independent HC plasma (1.25, 2.5, 5, 10 and 20%). Cells were analyzed on day 2 for surface expression of activation markers (CD25 and CD86) by flow cytometry. For the detection of IFN- $\gamma$ , TNF- $\alpha$  and IL-21 produced by T<sub>H</sub> cells, frozen peripheral blood mononuclear cells were thawed and  $10^6$  cells per well were plated in a 12-well culture plate and then rested overnight at 37°C in a CO<sub>2</sub> incubator. Cells were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of brefeldin A and monensin (eBioscience Cell Stimulation Cocktail 500 $\times$ ; Thermo Fisher Scientific) for 4 h then surface stained, followed by intracellular staining for cytokines and detected by flow cytometry.

For cT<sub>H1</sub> and naive B cell co-culture,  $5 \times 10^4$  sorted resting naive B cells (CD19<sup>+</sup>CD27<sup>-</sup>IgD<sup>+</sup>CD24<sup>int</sup>CD38<sup>int</sup>IgM<sup>+</sup>) (purity >98%) from an HC were co-cultured with  $2.5 \times 10^4$  cT<sub>H1</sub> cells sorted either from an independent HC or patient with pRD in a round-bottom 96-well culture plate in complete RPMI 1640 medium (100  $\mu$ l per well) supplemented with 10% heat-inactivated fetal bovine serum. The cells were mixed and cultured in the presence of endotoxin-reduced staphylococcal enterotoxin B (SEB) at 1  $\mu$ g ml<sup>-1</sup> for 7 d then plasma cells (live CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>hi</sup>) were detected among total B cells by flow cytometry.

**Monoclonal antibody cloning.** NE transitional (CD27<sup>-</sup>IgD<sup>+</sup>CD38<sup>hi</sup>CD24<sup>hi</sup>IgM<sup>hi</sup>CD21<sup>lo</sup>CD10<sup>+</sup>) and resting mature naive (CD27<sup>-</sup>IgD<sup>+</sup>CD38<sup>int</sup>CD24<sup>int</sup>IgM<sup>+</sup>CD21<sup>+</sup>CD10<sup>-</sup>) B cells were single sorted into dry 96-well PCR plates. RNA from single B cells was reverse-transcribed in the original 96-well plate in 10.5- $\mu$ l reactions containing 150 ng random hexamer primer (pd(N)6, Amersham Pharmacia Biotech), 0.5  $\mu$ l dNTP-Mix (10 mM each nucleotide), 1  $\mu$ l 0.1 M dithiothreitol, 0.5% v/v NP40, RNase inhibitors (0.8 U RNAsin, Promega) and 40 U Superscript II reverse transcriptase (Invitrogen) at 42°C for 55 min. Immunoglobulin heavy-chain, immunoglobulin  $\lambda$ -chain or immunoglobulin  $\kappa$ -chain transcripts were amplified by two rounds of PCR, restriction sites were introduced by the second PCR. PCR reactions contained 0.25  $\mu$ M primers, 1 U Hotstar Taq DNA polymerase (QIAGEN) and 3.5  $\mu$ l complementary DNA for first PCR in 20  $\mu$ l or 3.5  $\mu$ l first PCR product for second PCR in 25- $\mu$ l reactions. Each round of PCR was performed for 50 cycles at 94°C for 30 s, 57°C (heavy chain/ $\kappa$ -chain) or 60°C ( $\lambda$ -chain) for 30 s, 72°C for 55 s (first PCR) or 45 s (second PCR). Primer sequences are listed in Supplementary Table 5. All PCR products were purified, sequenced and analyzed by IMGT/V-QUEST as described in BCR repertoire analysis. Products were directly cloned into expression vectors containing human IgG1,  $\kappa$ -chain or  $\lambda$ -chain constant regions. Plasmids were sequenced to select clones with inserts identical to the original PCR product and used for monoclonal antibody production.

**Monoclonal antibody production and purification.** The 293A HEK fibroblasts were cultured in DMEM supplemented with 10% ultra-low IgG FCS (GIBCO) and co-transfected with 5  $\mu$ g of heavy- and light-chain-encoding plasmid DNA using polyethylenimine (PEI). Between 8–12 h after transfection, cells were washed with serum-free DMEM and cultured in DMEM supplemented with 1% Nutridoma SP (Roche). Supernatants were collected after 10 d of culture. For self-reactivity HEp-2 IFAs, antibodies were purified on protein G Sepharose (Amersham Pharmacia Biosciences).

**Poly- and self-reactivity tests.** Recombinant antibodies were tested with ELISA at concentrations of 1, 0.25, 0.0625 and 0.0156  $\mu$ g ml<sup>-1</sup> for anti-dsDNA, insulin and LPS reactivity with two positive controls used in each assay to determine threshold for positive reactivity (defined as mean of positive controls minus 2 s.d. at 1  $\mu$ g ml<sup>-1</sup> antibody concentration). Antibodies were considered polyreactive when they recognized at least two of the three antigens tested. Recombinant antibodies were also tested for anti-HEp-2 cell line lysate reactivity with ELISA at a concentration of 5  $\mu$ g ml<sup>-1</sup>. Blank corrected absorbance values were normalized with the mean of positive controls minus 2 s.d. and values above 1 were considered positive for HEp-2 reactivity. For indirect immunofluorescence, assay recombinant antibodies

were incubated in 200  $\mu$ g ml<sup>-1</sup> concentration in HEp-2 cell-coated slides (MBL International) and detected according to the manufacturer's instructions.

**BCR repertoire analysis.** For preparation of the input heavy-chain sequences, bulk, pre-annotated heavy- and light-chain sequence data were generated by iRepertoire from the messenger RNA extracts of sorted B cells (25,000–50,000 cells per sample). To be consistent throughout our studies, we extracted all raw nucleotide sequences from these datasets and reannotated using IMGT/HighV-QUEST (program v.3.4.17, reference directory release, 201915-3)<sup>61</sup>. Unless specified otherwise, all further data processing steps were performed using algorithms of the Immcantation framework<sup>62</sup>, Tidyverse system (H. Wickham and G. Grolemond, R for Data Science) and the R language (v.3.6.3) (Extended Data Fig. 6a). IMGT annotated data were first converted to a standard adaptive immune repertoire (AIRR) rearrangement format with 'MakeDb.py' script of Change-O package (v.1.0.0)<sup>63</sup>. Copy numbers and isotypes were brought back to these repertoire datasets from the original iRepertoire annotations. For subsequent steps, only the CDR1-FWR4 region was kept everywhere. Separate records of identical sequences were collapsed into one unique record for each sequence summing their copy numbers. To reduce the potential bias originating from the errors of reverse transcription, amplification and sequencing, we utilized the following strategy: sequences with fewer than five copies were pulled out into a separate, low-copy pool retaining only a high-copy subset. Each low-copy sequence was matched to every high-copy sequence. If the Hamming distance between a low-copy sequence and a high-copy counterpart was not higher than one, then the low-copy sequence became merged into the high-copy pool by adding its copy number to the closest high-copy sequence. All other unmatched, low-copy sequences were discarded. Finally, all non-functional sequences were removed from the merged pool. Single-clone heavy-chain sequences of previously in vitro characterized, functional monoclonal antibodies of the individuals were annotated with IMGT in the same way as iRepertoire data.

For the treemap, to visualize diversity, we plotted the relative frequencies of the most abundant 2,500 clones on treemaps categorized by 58 V<sub>H</sub> gene families. Divergent color hues were assigned to different V<sub>H</sub> genes unified across all repertoires. Distinct clones sharing the same V<sub>H</sub> gene were displayed using altered brightness of the same hue. Treemaps were plotted with the 'treemap' function from treemap R package<sup>64</sup>.

For gene usage, V, D and J gene usages were quantified by calling the 'countGenes' R function (Alakazam v.1.0.2 package) on repertoires.

For the SHM profile, SHM levels were measured with the 'observedMutations' function (SHazaM v.1.0.2) for each sequence and the mean of these values was used. The 5-mer nucleotide motif mutability probability values or SHM-targeting model in each compartment was calculated by 'createTargetingModel' function and visualized as linear or circular ('hedehog') bar graphs using the 'plotMutability' function (SHazaM v.1.1.0). Descriptive indices (D50, Shannon–Wiener and Gini–Simpson) were calculated implementing standard statistical formulas in R.

For Bayesian estimation of antigen-driven selection (BASELINE), an established method was followed to quantify antigen selection<sup>65–67</sup>. In each sequence dataset (repertoires, random downsampled subsets or clonotype lineages), first the posterior probability density function for every single sequence was calculated by using 'calcBaseline'. Mean selection strength (mean Sigma), the 95% confidence intervals and P values were determined with 'summarizeBaseline' function (both from SHazaM v.1.0.2 package). Sigma values were color-coded using a blue–gray–red palette (negative–zero–positive) to demonstrate selection strength of single sequences on corresponding figures.

For unsupervised clonal clustering of heavy-chain sequences, initially, we attempted to apply the 'findThreshold' method (SHazaM v.1.0.2 package) as a part of the automatic grouping of closely related clonotype sequences but it failed in a proportion of the patients with pRD. Hence, we developed an algorithm for this task to keep the main concept of detecting and working with a distance threshold similar to the mentioned procedure. Briefly, Hamming distances of nearest neighbors of each heavy-chain sequences were calculated by the 'distToNearest' R function (SHazaM v.1.0.2 package) using sequence length normalization (mode, 'ham'; normalize, 'len'; and first, 'FALSE'). The histogram representing these distances in the repertoire was smoothed and after the first peak, the position of the first non-declining value instead of the previously used local minimum was determined. Subsequently, this position as the distance threshold was used to generate clonotype clusters utilizing the 'DefineClones.py' script (–mode gene–act set–norm len–model ham). Putative closest germline sequences were added to the prepared and clonally grouped data by 'CreateGermlines.py' algorithm (–g dmask–cloned).

For identification of the relatives of cloned heavy-chain sequences (ImmChainTracer pipeline), we assembled a pipeline (ImmChainTracer) that collects close relatives of in vitro characterized and IMGT annotated, single-clone, naive B cell-derived heavy-chain sequences in specified repertoires. The Hamming distance threshold was determined on the full target repertoire for subsequent clonotype clustering. V, J gene and junction length properties of the input single-cell DNA sequence were applied as filter criteria to exclude the majority of non-relevant sequences and to reduce the size of the target repertoire substantially making a pre-filtered 'mini repertoire'. Input DNA sequence data in question

were added to this reduced AIRR dataset. Clonal clustering in this combined, pre-filtered AIRR dataset grouped all related sequences around the input sequence. All sorted members of the queried B cell lineage were revealed by the extraction and merging of such groups (clonotypes) of sequences from all compartments of the individual.

For clonal connectivity within compartments (lineage network diagrams), phylogenesis of related B cells inside clonotype clusters was inferred by the DNA parsimony approach in 'dnapsars' program (PHYLIP v.3.697 software package J. Felsenstein, 'PHYLIP, Phylogeny Inference Package' (v.3.2)) embedded in the Alakazam module (v.1.0.2 package) and represented as graphs or trees using the igraph (v.1.2.5) R library (G. Csardi and T. Nepusz). Network diagrams were plotted as a multilayered graph set consisting of 2,500 unique, randomly selected, clonally grouped sequences, where nodes represent distinct heavy-chain sequences (single clones) and edges bind only related sequences (clones). Size of the nodes refer to the abundance of corresponding clones on a logarithmic scale. Different coloring schemes of the nodes were used to demonstrate compartment affiliation, mutation burden, isotype or antigen selection strength.

For clonal connectivity among compartments (circular visualization plots), first, CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> (or NE in case of infant donors) repertoire data were randomly downsampled to 10,000 sequences. Abundance of each sequence and clonal connections between related clones in different compartments were visualized using circular visualization plots using an already published algorithm<sup>39</sup>.

**TCR repertoire analysis.** Annotated TCR-V $\beta$  sequence data were generated by Adaptive Biotechnologies from the DNA extracts of 25,000–50,000 sorted Treg and cTfh cells. Data for graphical representation of TCR-V $\beta$  gene rearrangements, CDR3 length and Simpson clonality index were generated and extracted using the Adaptive Immunoseq Analyzer 3.0 software. All fasta data files generated for the analyses are available in the NCBI submission portal under accession code [PRJNA746291](https://www.ncbi.nlm.nih.gov/submit/PRJNA746291).

**Statistical analysis.** Statistical analyses were performed using GraphPad Prism (v.9) or R software. Statistical analyses were two-sided. For two groups, statistical analyses were performed using unpaired Student's *t*-tests. A Mann–Whitney *U*-test was used when data did not follow normal distribution according to the Shapiro–Wilk test. For more than two groups, statistical analyses were performed using a Mann–Whitney *U*-test with multiple comparison (Holm–Šidák method). In all graphs each dot represents one individual and results are shown as the mean  $\pm$  s.e.m. Correlations between two variables were assessed using nonparametric Spearman correlation tests. *P* values were considered significant at *P* < 0.05 and are shown on each graph when reaching statistical significance between groups. Each assay was carried out with as many patients as were available. No statistical methods were used to pre-determine sample sizes.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

BCR repertoire sequencing data that support the findings of this study have been deposited in the NCBI submission portal under accession code ([PRJNA746291](https://www.ncbi.nlm.nih.gov/submit/PRJNA746291)). iRepertoire pre-processed data files (iRepertoire\_preprocessed.zip), data files further processed by our analysis pipeline (prepared\_AIRR\_HC.zip and prepared\_AIRR\_pRD.zip) and the individual heavy-chain variable sequences cloned from single B cells (prepared\_AIRR\_single\_clone\_IgH\_sequences.zip) are available on GitHub (<https://github.com/blazsop/pRD-data>). All additional data needed to evaluate the conclusions in this study are present in the main text or Supplementary Information. TCR repertoire sequencing data are available under accession code [PRJNA746291](https://www.ncbi.nlm.nih.gov/submit/PRJNA746291). Source data are provided with this paper.

## Code availability

Custom analysis scripts are available on GitHub (<https://github.com/blazsop/airmine/>).

## References

- Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. *Cytom. A* **87**, 636–645 (2015).
- Alamyar, E., Duroux, P., Lefranc, M. P. & Giudicelli, V. IMGT((R)) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. *Methods Mol. Biol.* **882**, 569–604 (2012).
- Gupta, N. T. et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. *Bioinformatics* **31**, 3356–3358 (2015).
- Vander Heiden, J. A. et al. AIRR community standardized representations for annotated immune repertoires. *Front. Immunol.* **9**, 2206 (2018).
- Tennekes, M. treemap: Treemap Visualization. R package version 2.4-2 <https://CRAN.R-project.org/package=treemap> (2017).
- Uduman, M. et al. Detecting selection in immunoglobulin sequences. *Nucleic Acids Res.* **39**, W499–W504 (2011).
- Yaari, G., Uduman, M. & Kleinstein, S. H. Quantifying selection in high-throughput immunoglobulin sequencing data sets. *Nucleic Acids Res.* **40**, e134 (2012).
- Yaari, G. et al. Models of somatic hypermutation targeting and substitution based on synonymous mutations from high-throughput immunoglobulin sequencing data. *Front. Immunol.* **4**, 358 (2013).

## Acknowledgements

We thank L. Fesus and R. Kiraly (University of Debrecen) for providing recombinant human tissue transglutaminase. We thank G. Mueller for her contribution to the experiments (Johns Hopkins All Children's Hospital/Children's Research Institute). We thank B. Schachter (Beth Schachter Consulting) for careful review and editing of the manuscript. We thank A. Leiss-Piller (Immunology Outpatient Clinic) and I. Kingyue Chinn (Center for Human Immunobiology, Texas Children's Hospital) for assisting in variant resolution. We thank H. L. Monforte (Johns Hopkins All Children's Hospital) for providing a paraffin-embedded spleen tissue block from a healthy individual. This work was supported by the National Institutes of Health (NIH National Institute of Allergy and Infectious Diseases (NIAID) 5K08AI103035, sub-R01AI100887-05 and R01AI153830-05 to J.E.W.), Robert A. Good Endowment, University of South Florida (to J.E.W.), Jeffrey Modell Foundation (to J.E.W.), NIH/NIAID grant AI-061093 (to E.M.) and by the Division of Intramural Research, NIAID, NIH (grant ZIA AI001222-04 to L.D.N.). Research laboratory studies were performed on de-identified samples under IRB approved protocols at University of South Florida (USF-Pro00035468 (PI, J.E.W.), USF-Pro00025693 (PI, J.E.W.)) and Johns Hopkins Medical Institute/Johns Hopkins All Children's Hospital (JHMI-IRB00175372 (PI, J.E.W.), JHMI-IRB00097062 (PI, J.W.L.) and JHMI-IRB00097938 (PI, J.W.L.)).

## Author contributions

K.C. and J.E.W. conceptualized the study, designed all experiments and directed the study. K.C., J.E.W., B.U., P.B. and L.D.N. wrote the manuscript with input from all authors. K.C., B.U., S.G., K.W., M. Stowell, L.H., R.C. and B.Z. performed the experiments and analyzed data. J.L.H. performed immunostaining, confocal imaging and image analysis of autoantibodies and human spleen; and revised the manuscript. T. Kawai and L.D.N. determined recombinase activity of new RAG variants. J.N., S. Pittaluga and G. Smith interpreted histological sections. M.A. performed viral load detection. P.B., K.C., B.U. and C.M.T. assembled and developed the BCR repertoire data processing computation framework, analyzed and interpreted data. C.B.G. assisted with variant resolution. M.E. coordinated the procurement of patient samples. L.D.N., M.P.C., S. Pillai, E.M., M.J.B., A.K., J.F.D. and M.K. contributed with conceptual design, interpretation of data and critically reviewed the manuscript. J.E.W. obtained funding and provided supervision. J.W.L., W.A.H., M.B.D., O.F., E.F., V.K., M. Svaton, S.E.H., J.D.H., T. Kuijpers, S.M.K., E.N., T.M., A.S., D.M., B.N., T.S., R.S., S. Savic, S. Sharapova, J.S., G. Sunkersett, B.R.W. and M.J.B. contributed with patient samples and provided genetic and clinical information. All authors critically reviewed, discussed the results, contributed to and agreed to the final manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information




**Extended data** is available for this paper at <https://doi.org/10.1038/s41590-022-01271-6>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41590-022-01271-6>.

**Correspondence and requests for materials** should be addressed to Krisztian Csomos or Jolan E. Walter.


**Peer review information** *Nature Immunology* thanks Joanne Reed and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. **Primary Handling Editor:** L. A. Dempsey, in collaboration with the *Nature Immunology* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



Extended Data Fig. 1 | See next page for caption.


**Extended Data Fig. 1 | RAG1/2 mutations, recombinase activity and clinical features. (a) Distribution of mutations in the RAG1/2 genes.** Mutations are indicated for each patient as patient ID and mutant alleles, with *a* and *b* separately for compound heterozygous or *ab* for homozygous variants. Core and non-core regions of the RAG proteins are denoted by gray and white, respectively. RAG1 domains: central non-core (CND), zinc dimerization (ZDD), nonamer-binding (NBD), dimerization and DNA-binding (DDBD), pre-RNase H (PreR), catalytic RNase H (RNH), zinc-binding (with cysteine and histidine zinc-binding residues (ZnC2 and ZnH2)) and carboxy-terminal (CTD). The RAG2 core region is a six-bladed propeller domain (6-BPD). Non-core RAG2 contains a plant homology domain (PHD). Numbers indicate amino acids at domain borders. **(b) Residual RAG recombinase activities by variants.** RAG recombinase activities are shown as percentage of wild-type variants for both alleles (see Supplementary Table 2 for details). Patient information with clinical presentations is shown (M: male, F: female, A: adenovirus, V: varicella, H: herpesvirus, EBV: Epstein-Bar virus, AIHA: autoimmune hemolytic anemia, ITP: immune/idiopathic thrombocytopenic purpura, AN: autoimmune neutropenia, VA: vasculitis, AL: alopecia, AR: arthritis, MAS: macrophage activation syndrome, HSM: hepatosplenomegaly, VI: vitiligo, ILD: interstitial lung disease, P: psoriasis, MG: myasthenia gravis). **(c-f) Lymphocyte counts in pRD patients.** Graphs show CD19<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup> lymphocyte counts in the peripheral blood of pRD-N (n = 1) and pRD-Ag patients (n = 16) in age groups 3-6 month, 2-6 years and over 12 years, compared to published aged-matched healthy ranges. Values for HCs are presented as floating bars with medians and 10<sup>th</sup> percentiles and 90<sup>th</sup> percentiles shown obtained as 3-6 month (n = 81), 2-6 years (n = 90) and over 12 years (n = 90), from published data. Values for patients are depicted individually.



Extended Data Fig. 2 | See next page for caption.




**Extended Data Fig. 2 | Autoantibody detection from plasma samples. (a) Immunofluorescent analysis (IFA) of plasma samples on Hep2 slides using confocal microscopy.** Representative confocal microscopy images of Hep2 slides stained with HC-Ags ( $n=7$ ), pRD-N ( $n=1$ ) and pRD-Ags patients ( $n=12$ ) plasma samples and detected with anti-IgG (green). Staining for all samples were performed simultaneously in a single experiment with two technical replicates for each. Score is depicted in left bottom corner for each sample. Nucleus (DAPI, blue), cytoplasm (Evans Blue, red). Magnification: 60x. **(b) Quantification of cytoplasmic and nuclear Hep2 positivity.** Bars represent mean $\pm$ s.e.m. with individual values from HC-Ags ( $n=7$ ), pRD-N ( $n=1$ ) and pRD-Ags patients ( $n=12$ ). Two-sided unpaired Student's *t*-test. **(c) Heatmap of autoantigen reactivities.** Binding of plasma IgGs to a set of autoantigens (human embryonic kidney 293 cell protein extract, human M2 antigen, intrinsic factor, proliferating cell nuclear antigen, tissue transglutaminase, threonyl-tRNA Synthetase, Ro/SSA (52 kDa), thyroid peroxidase, U1-SnRNP C protein, thyroglobulin, ribosomal phosphoprotein P0, IFN- $\alpha$ , IFN- $\omega$ , IL-12, single and double stranded DNA) were measured with ELISA in 400x dilution. Blank corrected absorbance values are shown by HC-Ags ( $n=10$ ), pRD-N ( $n=1$ ) and pRD-Ag ( $n=14$ ) subjects. Antigens, with z score above 2 in three or more patients were considered as common autoantigens and are labeled with bold (left). Statistical analysis was performed using two-sided unpaired Student's *t*-test on Ag-experienced subjects (excluding pRD-N, P1). *P* values for differences between HC-Ags and pRD-Ag patients are shown (right) and the statistically significant differences are depicted by red. **(d) Anti-cytokine auto-Ab levels.** Binding of plasma IgGs to IFN- $\alpha$ , IFN- $\omega$ , IL-12 was measured with ELISA in 2-fold serial dilution (200-1,600-fold). **(e) IgM 9G4 auto-Ab levels.** Plasma 9G4 auto-Abs were measured with ELISA in 2x serial dilution (100 - 204,800-fold). Cut-off for positivity on **b** and **c** is indicated with green dashed line defined as  $z=2$  at each dilution. Mean values of HC-Ags for **c** and **d** ( $n=11$  or 4, respectively) are depicted with thick black line and dark gray circles, individual values for pRD-N ( $n=1$ ) and pRD-Ag ( $n=14$ ) patients are shown. ELISAs for **c-e** were performed with two technical replicates.




Extended Data Fig. 3 | See next page for caption.

**Extended Data Fig. 3 | Automated unsupervised B cell subset identification by FlowSOM. (a). Minimal spanning tree (MSP).** MSPs were built as described in Methods to visualize similar nodes in branches and their relative connection to each other. Nodes are numbered as 1–100. **(b). Metaclustering.** Based on similarities, nodes were classified into 16 metaclusters (M0–15), each representing a unique B cell subset. **(c). Relative expression of surface markers.** Heat map represents the relative expression level of CD21, CD24, CD27, CD38, IgD and IgM on the B cells concatenated from four HC-Ags and four pRD-Ag patients by nodes. **(d) B cell subset assignment.** Metaclusters were assigned to B cell subsets as described in Methods. Novel subsets are depicted with asterisk. Subsets are organized according to possible developmental stages. Immunophenotypic definition of each subset is indicated. Heat map represents the normalized mean expression values of each surface markers for the HC-Ag ( $n=4$ ) and pRD-Ag patients ( $n=4$ ) separately corresponding to each metaclusters. Scale shows normalized value ranges for the expression of each marker defined as negative (–), low (lo), intermediate (int), positive (+) and high (hi). **(e) Subset frequencies by FlowSOM.** Frequencies of each metacluster from HC-Ags ( $n=4$ ) and pRD-Ag patients ( $n=4$ ) are shown as  $\text{mean} \pm \text{s.e.m.}$  with individual values. **(f) Subset identification by HyperFinder.** Two-dimensional sequential gating was constructed by HyperFinder FlowJo plugin using dual combinations of CD21, CD24, CD27, CD38, IgD and IgM parameters. Contour plots were generated on the data set concatenated from the four pRD-Ag patients and four age-appropriate HC-Ag. Fm-scores are inserted in the last plot of the sequential gating for each B cell subset. **(g) Cell number of the specific B cell subsets.** Data are shown as  $\text{mean} \pm \text{s.e.m.}$  with individual values from HC-Ag ( $n=11$ ), pRD-Ag ( $n=11$ ) and pRD-N ( $n=1$ ). Mann-Whitney  $U$  test with multiple comparison (Holm-Šidák method), P13 with lymphoproliferation was excluded from the analysis.





Extended Data Fig. 4 | See next page for caption.

**Extended Data Fig. 4 | Extended B cell phenotyping. (a) Fractioning B cells by conventional standard gating.** Plots show a representative HC-Ag, HC-N, pRD-Ag and the pRD-N subjects. **(b) Major B cell subset frequencies.** Frequencies of naive (CD27<sup>-</sup>IgD<sup>+</sup>), memory (CD27<sup>+</sup>), DN (CD27<sup>-</sup>IgD<sup>-</sup>) and plasmablast/plasmacell (CD27<sup>hi</sup>CD38<sup>hi</sup>) B cell populations are shown. **(c) Transitional, CD38<sup>int</sup> and CD38<sup>-</sup> subsets frequencies from CD27-IgD<sup>+</sup> gate.** **(d) Memory B cell subsets frequencies from CD27<sup>+</sup> gate.** For h-j statistical analyses were performed on Ag subjects (HC-Ag vs pRD-Ag) using Mann-Whitney *U* test with multiple comparison (Holm-Šidák method). Bars represent mean ± s.e.m. with individual values from HC-Ag (n = 13), pRD-Ag (n = 13), HC-N (n = 3) and pRD-N (n = 1). **(e) Detection of T-bet<sup>+</sup> B cells.** Gates show the CD21<sup>low</sup>T-bet<sup>+</sup> B cells in a representative from HC-Ag and a pRD-Ag patient. Frequencies are indicated. **(f) Gating for CD38<sup>int</sup>, CD38<sup>-</sup>, CD27<sup>+</sup> and DN (CD27-IgD<sup>-</sup>) B cells.** Plot show gatings from a representative HC-Ag and a pRD-Ag patient. **(g) T-bet expression in CD38<sup>int</sup>, CD38<sup>-</sup>, CD27<sup>+</sup> and DN (CD27-IgD<sup>-</sup>) B cells.** Overlaid histogram plots depict the T-bet expression by CD38<sup>int</sup>, CD38<sup>-</sup>, CD27<sup>+</sup> and DN (CD27-IgD<sup>-</sup>) B cells in a representative HC-Ag subject (black) and a pRD-Ag patient (red) in comparison to HC total B cell (filled gray). Expression levels are indicated as gMFI values. **(h) T-bet expression in CD38<sup>int</sup>, CD38<sup>-</sup>, CD27<sup>+</sup> and CD27-IgD<sup>-</sup> populations. Expression of FcRL4, FcRL5, CD85j and CXCR3 ABC-specific markers (i), CD95 (j) and BAFF-R (k) in CD38<sup>int</sup>, CD38<sup>-</sup>, CD27<sup>+</sup> and CD27-IgD<sup>-</sup> B cells.** Plots for e-g were obtained from a single experiment performed simultaneously on HC-Ags (n = 10) and pRD-Ag patients (n = 4). Data for h was obtained from a single experiment performed simultaneously on HC-Ags (n = 10) and pRD-Ag patients (n = 4). Data for i-k (except for CXCR3) was obtained from a single experiment performed simultaneously on HC-Ags (n = 13) and pRD-Ag patients (n = 5). Data for i CXCR3 panel was obtained from a single experiment performed simultaneously on HC-Ags (n = 6) and pRD-Ag patients (n = 4). Data for each graph are normalized and shown as in Fig. 1e and shown as mean ± s.e.m. with individual values depicted. Statistical analyses were performed using two-sided unpaired Student's *t*-test.



Extended Data Fig. 5 | See next page for caption.






**Extended Data Fig. 5 | Spleen pathology. (a)** Hematoxylin and eosin staining of spleen sections from a HC and a pRD-Ag subject. 40x magnifications. **(b)** Hematoxylin and eosin staining of spleen sections from a HC and a pRD-Ag subject. Follicles are depicted with yellow dashed line. 10x magnifications. **(c-f) Chromogenic staining for CD20 (c), CD21 (d), CD4 (e) and Bcl-2(f) in a pRD-Ag subject.** 50x magnifications. **(g) Cellular distribution shown by DAPI (nucleus) staining by confocal microscopy.** 10x magnification. **(h-i) Representative multi-color immunofluorescence images for T-bet expression in follicular (Fo) (h) and extrafollicular (EF) (i) areas.** Overlay shows CD19 (red), CD4 (green), T-bet (yellow) and DAPI (blue); and CD19 (red), CD4 (green) and T-bet (yellow) expressions are shown separately. 60x magnification. All images were obtained from the spleen sections of a single experiments performed simultaneously for a HC-Ag and a pRD-Ag (P5) subject.



Extended Data Fig. 6 | See next page for caption.




**Extended Data Fig. 6 | Repertoire analysis pipeline and B cell sorting. (a) Repertoire analysis pipeline.** See Methods for details. **(b) Gating and sort purity of batch sorted CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells.** Gating is shown for a HC-Ag and a pRD-Ag subject analyzed parallel in the same experiment, and are representative of six independent experiment, HC-Ag (n = 6), pRD-Ag (n = 5) and pRD-N (n = 1).




Extended Data Fig. 7 | See next page for caption.

**Extended Data Fig. 7 | BCR repertoire. (a) IGH-V-D-J gene usage from CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells.** Heat maps represent the frequency of each V<sub>Hr</sub>, -D<sub>H</sub> and -J<sub>H</sub> gene by subjects, HC-N (n=1), HC-Ag (n=5), pRD-N (n=1), pRD-Ag (n=5-6) shown as mean±s.e.m. with individual values. Subject IDs are depicted on the left side of each heat map; and compartments as CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells depicted with blue, red, and green on the left. Ig V<sub>Hr</sub>, -D<sub>H</sub> and -J<sub>H</sub> genes are listed on the bottom by their chromosomal order. Color scales represent gene frequencies for each family separately. *d.*: distal genes, *p.*: proximal genes. Statistical analysis was performed using two-sided unpaired *t*-test with multiple comparison (Holm-Šidák method) to compare V<sub>Hr</sub>, -D<sub>H</sub> and -J<sub>H</sub> gene usage between HC-Ag and pRD-Ag donors and P values are indicated when reached significance. Plot inserts shows changes in gene usages in CD38<sup>-</sup> and CD27<sup>+</sup> cell compartments compared to the values of HC-Ags in CD38<sup>int</sup> compartment (horizontal black line) for HCs (gray) and pRD patients (red), infant donors (triangles), and antigen-experienced donors (circles). **(b) "Hedgehog" plots - targeted hot- and coldspot sequence motifs.** Frequencies of WRCY/RGYW (red), SYC/GRS (blue), WA/TW (green) and neutral (gray) mutations are visualized. **(c) Enumeration of different SHM hot- and coldspots in CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells.** Graph shows mutation frequency in different SHM hot- and coldspots from HC-N (n=1), HC-Ag (n=5), pRD-N (n=1), pRD-Ag (n=5) shown as mean±s.e.m. with individual values. **(d) IgG surface expression.** Contour plots show the surface expression of IgG and IgM of a representative HC-Ag (dark gray) and a pRD-Ag patient (red) overlayed from their CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells separately. **(e) Frequency of B cells based on IgM and IgG surface marker expression.** Graphs show frequency of IgM<sup>+</sup> IgG<sup>-</sup>, IgM<sup>+</sup> IgG<sup>dim</sup>, IgM<sup>-</sup> IgG<sup>+</sup>, IgM<sup>-</sup> IgG<sup>-</sup> from CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cells and shown as mean±s.e.m. with individual values. Statistical analysis was performed on Ag-experienced subjects using Mann-Whitney *U* test. Data for **d-e** was obtained from HC-N (n=3), HC-Ag (n=15), pRD-N (n=1), pRD-Ag (n=11).




Extended Data Fig. 8 | See next page for caption.

**Extended Data Fig. 8 | Impaired central B cell tolerance. (a) Gating and sort purity of index single-cell sorted new emigrant transitional and CD38<sup>int</sup> B cells.** Pre-sort plots show the original composition of B cells in the samples before single-cell sort. Post-sort plots show the phenotype of the 46 or 94 new emigrant or CD38<sup>int</sup> B cells index single-cell sorted into 96-well plate. Gating is shown for a representative HC-Ag subject, experiment was performed for HC-Ag (n = 3), pRD-Ag (n = 5) and pRD-N (n = 1). **(b) Binding of Abs from new emigrant transitional B cells to dsDNA, insulin and LPS.** Abs cloned from new emigrant transitional B cells of pRD-N patient (P1) were tested for anti-dsDNA, insulin and LPS reactivity in serial dilution. Thick black lines with blue circles show binding of the two positive controls used in each assay to determine threshold for positive reactivity (mean of positive controls minus 2SD at 1.0 µg/ml). Threshold for positive reactivity is shown with green dashed line. **(c) Frequency of polyreactive new emigrant transitional B cell clones.** The frequency of non-polyreactive (open area) and polyreactive (filled area) clones is summarized in pie chart. Abs were considered polyreactive when they recognized at least two of the three antigens tested. The total number of clones tested is indicated. **(d-e). Frequency of J<sub>κ</sub> (d) and J<sub>λ</sub> (e) light chain gene segments in repertoires.** Data are shown as mean ± s.e.m. with individual values for each gene segments in CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> B cell repertoires of pRD patients (n = 3) and HCs (n = 3). Statistical analysis was performed using Two-sided unpaired t-test with multiple comparison. **(f) Gating for kappa and lambda light chain expression.** Representative plots are shown for a HC-Ag and pRD-Ag patient. **(g) Kappa and lambda light chain expression.** Data are shown as mean ± s.e.m. with individual values. Statistical analysis was performed using two-sided unpaired Student's t-test. **(h) Ratios of kappa:lambda light chain expression.** Graph shows the relative ratio of kappa:lambda light chain expression as means. Data for f-h was obtained from a single experiment performed simultaneously on HC-Ags (n = 12) and pRD-Ag (n = 4) subjects.



**Extended Data Fig. 9 | Clonal correlations and diversification. (a,b) Clonal expansion with somatic hypermutation, isotype switches and antigen selection in CD38<sup>-</sup> and CD27<sup>+</sup> B cell compartments.** Lineage network diagrams were generated for CD38<sup>-</sup> (a), and CD27<sup>+</sup> B cell (b) compartments as described in Fig. 6a and Methods. One representative HC-Ag is shown from n=5, and all other sequenced subjects are shown (HC-N, n=1, pRD-N n=1 and pRD-Ag n=5). (c) **Clonal sharing between CD38<sup>int</sup>, CD38<sup>-</sup> and CD27<sup>+</sup> repertoires.** Clonal relatedness is shown as in Fig. 6c for the all the additional investigated subjects not shown in Fig. 6c. Note that no sufficient amount of CD38<sup>-</sup> cells was available from either infant donor, however, repertoire analysis was possible from new emigrant transitional cells (NE), therefore, circular visualization plots were generated for the infant subjects on the NE, CD38<sup>int</sup> and CD27<sup>+</sup> compartments.



Extended Data Fig. 10 | See next page for caption.



**Extended Data Fig. 10 | T cells. (a) Representative multi-color immunofluorescence image of spleen sections.** Overlaid markers are shown as CD19 (red), CD4 (green), PD-1 (violet), and DAPI (blue) staining performed simultaneously in a single experiment for spleen sections from a HC and a pRD patient. Red arrow: T cell region, light blue arrow: GC light zone, dark blue arrow: GC dark zone. Magnification: 20x. **(b) PD-1 expression.** Magnification: 60x. **(c) PD-1 expression.** Magnification: 60x, yellow arrow depicts Tfh cells (CD4<sup>+</sup>PD-1<sup>+</sup>). **(d) Gating for naive, CM, EM TEMRA T<sub>H</sub> cell subsets. (e) Enumeration of T cell subsets.** Data were obtained from HC-N (n=1), HC-Ags (n=10), pRD-N (n=1) and pRD-Ags (n=8) subjects. **(f) Productive Simpson clonality of cTfh TCR-V $\beta$  repertoires. (g) CDR3 length distribution in cTfh TCR-V $\beta$  repertoires.** Means of HCs and pRD patients are depicted as a black and red line, respectively. Individual values are shown for the patients. nt - nucleotides. **(h) CDR3 length of cTfh TCR-V $\beta$  repertoires. (i) Differential usage of V genes in cTfh TCR-V $\beta$  repertoires.** Relative frequency of TCR-V $\beta$  family usages is shown. **(j) Productive Simpson clonality of Treg TCR-V $\beta$  repertoires. (k) CDR3 length distribution in Treg TCR-V $\beta$  repertoires.** Means of HCs and pRD patients are depicted as a black and red line, respectively. Individual values are shown for the patients. **(l) CDR3 length of Treg TCR-V $\beta$  repertoires. (m) Differential usage of V genes in Treg TCR-V $\beta$  repertoires.** Relative frequency of TCR-V $\beta$  family usages is shown. All TCR-V $\beta$  repertoire data were obtained on HC-Ag (n=7) and pRD-Ag (n=6) subjects. **(n) Gating strategy for sorted CD38<sup>int</sup> B and cTfh cells.** Gating and sort purity of batch sorted CD38<sup>int</sup> B cells and cTfh cells for co-culture assay shown on a representative HC-Ag subject. Four independent experiments were performed with one HC-Ag (n=4) and one pRD-Ag (n=4) subjects in each. Data for e-f h-j and l-m are shown as mean $\pm$ s.e.m. with individual values. Statistical analysis was performed using two-sided unpaired Student's *t*-test for panel f-h and j-l, or Mann-Whitney *U* test with Holm-Šidák multiple comparison for panel e, i and m.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Flow cytometry data were collected on a FACSAria II (BD Biosciences) with FACSDiva software version 10. Immunohistochemistry was performed on a Leica DM LB2 clinical brightfield microscope (Leica Microsystems Inc.) using Leica Application Suite V4.9 software. Confocal microscopy images were performed on Nikon NIS-Elements AR Analysis 4.40 software. ELISA plates were read on an EnSpire Workstation (PerkinElmer) (EnSpire software version 4.13.3005.1482). B cell receptor (BCR) sequencing data was generated, preprocessed, and provided by iRepertoire. Custom analysis scripts are available on GitHub (<https://github.com/blazsop/airmine/>).

Data analysis

The analysis of flow cytometry data was performed using FlowJo software (version 10.7.1) and FlowJo plugins including FlowSOM (v2.5), tSNE (v2.0), Hyperfinder (v0.6.2) and DownSample (v3.0). Data representation and statistical analysis was performed using Graphpad Prism (version 9.1.0). BCR repertoire analysis was performed using IMGT/HighV-QUEST (version: 3.4.17, reference directory release: 201915-3) and R (version 4.0.4, 2021-02-15) on a x86\_64-pc-linux-gnu (64-bit) platform. T cell repertoire data was analyzed with Adaptive Immunoseq Analyzer 3.0 software.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

BCR and TCR repertoire sequencing data that support the findings of this study have been deposited in the NCBI submission portal under accession code PRJNA746291. iRepertoire pre-processed data files (iRepertoire\_preprocessed.zip), data files further processed by our analysis pipeline (prepared\_AIRR\_HC.zip and prepared\_AIRR\_pRD.zip) and the individual IgH variable sequences cloned from single B cells (prepared\_AIRR\_single\_clone\_IgH\_sequences.zip) are available on GitHub (<https://github.com/blazsop/pRD-data>). All additional data needed to evaluate the conclusions in this study are present in the main text or Supplementary Information. Pathogenicity of RAG mutations was assessed based on data obtained from ClinVar database: <https://www.ncbi.nlm.nih.gov/clinvar/>

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	This study is purely explorative performed on a cohort of patients carrying hypomorphic pathogenic RAG1 or 2 gene variants and presenting with combined immune deficiency with granuloma / autoimmunity phenotype. This is a rare disease with an estimated frequency of 1:150,000 of the human general population. Therefore, no statistical methods were conducted for sample-size calculation prior to patient enrollment due to the nature of the study and patients. All designed experiments were performed on the patient lymphocyte or plasma samples depending on sample availability. In all experiments data were generated on sample sizes with at least 4 patients (and healthy control) samples per group, representing biological replicates.
Data exclusions	<p>Flow cytometry data were excluded from the experiment and statistical analysis when cell abundance was less than 1,000 cells in target gate. Chronic clinical viremia with high viral load of EBV and CMV caused marked B cell proliferation in P13 not reflecting intrinsic B cell characteristic in this patient. Therefore, this single data point was excluded from data representation and analysis when we analyzed B cell number in peripheral blood of the pRD patients (Extended data Figure 4).</p> <p>As infant subjects (both healthy and patient) display different immunophenotypic features and BCR repertoire characteristics compared to antigen experienced subjects, these data points were excluded from all statistical analysis presented in the study. However, for representation and comparison with antigen experienced subjects, data from infants were included in all figures with different symbols when available. All details are described in corresponding legends for each figure.</p> <p>Sample exclusion: blood samples were not used if not processed within 48 hours of blood collection.</p>
Replication	<p>Biological replicates were used in the study for flow cytometry immunophenotyping, in vitro cultures and BCR repertoire analysis based on patient sample availabilities as detailed in each figure legend .</p> <p>For the generation of recombinant antibodies, cloning was performed in duplicates from each sorted B cells. Only clones representing identical Ig heavy chain DNA sequences (and light chain sequences) were used for antibody expression and reactivity tests. All attempts for replication were successful.</p> <p>ELISA assays were performed with duplicates and with serial dilutions of the plasma samples. All attempts for replication were successful.</p> <p>In vitro functional assays on lymphocytes were performed with two or three replicates when applicable as indicated in corresponding figure legends. All attempts for replication were successful.</p> <p>Replication of BCR repertoire sequencing from the same subject was not feasible in this study. Therefore, it was performed one time from each subject and data from different subjects represents biological replicates by study groups. P14 is an exception as BCR repertoire sequencing was performed at two different time points on this subject as indicated in legend of Figure 5.</p>
Randomization	<p>Randomization was not relevant to our study due to the nature of the disease and patient subjects. All available patients were included in the study and used for experiments if met the enrollment criteria described in Methods.</p> <p>For all experiments, aged range-matched healthy donor samples were used in parallel with the patient samples to ensure accuracy of the assay and serve as data for healthy controls in the statistical analysis.</p> <p>Exclusion criteria for healthy subjects are specified in Methods.</p>

Blinding No blinding was applied due to the nature of the study performed on rare patient subjects (only ex vivo experiments were performed. Researchers were involved in obtaining patient blood samples, organizing and receiving sample shipments, performing and analyzing experiments, hence, blinding was not applicable)

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).
Research sample	State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.
Sampling strategy	Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Data collection	Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Timing	Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Non-participation	State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.
Randomization	If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

## Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.
Research sample	Describe the research sample (e.g. a group of tagged <i>Passer domesticus</i> , all <i>Stenocereus thurberi</i> within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.
Sampling strategy	Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Data collection	Describe the data collection procedure, including who recorded the data and how.
Timing and spatial scale	Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Reproducibility	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Randomization	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.
Blinding	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Did the study involve field work?  Yes  No

## Field work, collection and transport

Field conditions	<i>Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).</i>
Location	<i>State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).</i>
Access & import/export	<i>Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).</i>
Disturbance	<i>Describe any disturbance caused by the study and how it was minimized.</i>

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

#### Flow cytometry:

Anti-human-CCR7, A-700 (Biolegend, Clone: G043H7, Cat# 353243, Lot#: B265544, Dil: 1:100)  
 Anti-human-CD10, PE-Cy7 (Biolegend, Clone: HI10a, Cat# 312214, Lot#: B267333, Dil: 1:100)  
 Anti-human-CD11c, PE-Cy5 (Biolegend, Clone: 3.9, Cat# 301610, Lot#: B291986, Dil: 1:80)  
 Anti-human-CD127, BV605 (Biolegend, Clone: A019D5, Cat# 351333, Lot#: B202926, Dil: 1:100)  
 Anti-human-CD19, APC-R700 (BD Biosciences, Clone: HIB19, Cat# 564977, Lot#: 0330615, Dil: 1:50)  
 Anti-human-CD19, PE/Cy5 (Biolegend, Clone: HIB19, Cat# 302216, Lot#: B263542, Dil: 1:200)  
 Anti-human-CD21, APC (Biolegend, Clone: Bu32, Cat# 354906, Lot#: B284909, Dil: 1:60)  
 Anti-human-CD21, PE-CF594 (Biolegend, Clone: Bu32, Cat# 354922, Lot#: B266487, Dil: 1:125)  
 Anti-human-CD24, BV510 (Biolegend, Clone: ML5, Cat# 311126, Lot#: B256187, Dil: 1:250)  
 Anti-human-CD25, PE (Biolegend, Clone: BC96, Cat# 302606, Lot#: B296102, Dil: 1:25)  
 Anti-human-CD27, BV421 (Biolegend, Clone: O323, Cat# 302824, Lot#: B301442, Dil: 1:100)  
 Anti-human-CD27, PE (Biolegend, Clone: O323, Cat# 302808, Lot#: B236590, Dil: 1:100)  
 Anti-human-CD38, PerCP-Cy5.5 (Biolegend, Clone: HIT2, Cat# 303421, Lot#: B168290, Dil: 1:250)  
 Anti-human-CD38, FITC (Biolegend, Clone: HB-7, Cat# 356610, Lot#: B178147, Dil: 1:100)  
 Anti-human-CD38, PE (Biolegend, Clone: HIT2, Cat# 303506, Lot#: B273752, Dil: 1:250)  
 Anti-human-CD38, BB700 (BD Biosciences, Clone: HIT2, Cat# 566445, Lot#: 0220490, Dil: 1:166)  
 Anti-human-CD4, FITC (Biolegend, Clone: RPA-T4, Cat# 300506, Lot#: B175118, Dil: 1:200)  
 Anti-human-CD45RA, PE-Cy5 (Biolegend, Clone: HI100, Cat# 304110, Lot#: B204601, Dil: 1:250)  
 Anti-human-CD69, PE-Cy7 (Biolegend, Clone: FN50, Cat# 310912, Lot#: B259693, Dil: 1:50)  
 Anti-human-CD80, FITC (Biolegend, Clone: 2D10, Cat# 305205, Lot#: B273868, Dil: 1:80)  
 Anti-human-CD86, APC (Biolegend, Clone: IT2.2, Cat# 305412, Lot#: B173001, Dil: 1:50)  
 Anti-human-CD138, BV605 (Biolegend, Clone: MI15, Cat# 356520, Lot#: B284321, Dil: 1:100)  
 Anti-human-CXCR5, PE (Biolegend, Clone: J252D4, Cat# 356904, Lot#: B283577, Dil: 1:200)  
 Anti-human-CXCR5, BV421 (Biolegend, Clone: J252D4, Cat# 356920, Lot#: B252332, Dil: 1:500)  
 Anti-human-HLA-DR, PE-Cy5 (Biolegend, Clone: L243, Cat# 307607, Lot#: B283127, Dil: 1:500)  
 Anti-human-ICOS, APC (Biolegend, Clone: C398.4A, Cat# 313509, Lot#: B248382, Dil: 1:200)  
 Anti-human-IgD, A-700 (Biolegend, Clone: IA6-2, Cat# 348229, Lot#: B222292, Dil: 1:125)  
 Anti-human-IgD, BV605 (Biolegend, Clone: IA6-2, Cat# 348232, Lot#: B277503, Dil: 1:250)  
 Anti-human-IgG, BB515 (BD Biosciences, Clone: G18-145, Cat# 564581, Lot#: 8303637, Dil: 1:500)  
 Anti-human-IgG, FITC (Biolegend, Clone: HP6017, Cat# 409310, Lot#: B272569, Dil: 1:250)  
 Anti-human-IgM, PE-CF594 (BD Biosciences, Clone: G20-127, Cat# 562539, Lot#: 0098775, Dil: 1:100)  
 Anti-human-IgM, PerCP-Cy5.5 (Biolegend, Clone: MHM-88, Cat# 314511, Lot#: B268270, Dil: 1:250)  
 Anti-human-PD-1, PE-Cy7 (Biolegend, Clone: EH12.2H7, Cat# 329918, Lot#: B298289, Dil: 1:80)  
 Anti-human-IFN $\gamma$ , PE-Cy7 (Biolegend, Clone: B27, Cat# 506518, Lot#: B182253, Dil: 1:125)  
 Anti-human-IL-10, PE-Cy7 (Biolegend, Clone: JES3-9D7, Cat# 501419, Lot#: B308621, Dil: 1:100)  
 Anti-human-TNF- $\alpha$ , PerCP-Cy5.5 (Biolegend, Clone: MAb11, Cat# 502926, Lot#: B171068, Dil: 1:200)  
 Anti-human-IL-21, APC (Biolegend, Clone: 3A3-N2, Cat# 513007, Lot#: B256205, Dil: 1:100)

Anti-human-CD3, BB515 (BD Biosciences, Clone: UCHT1, Cat# 564466, Lot#: 6315656, Dil: 1:100)  
 Anti-human-IFN- $\gamma$ , APC Biolegend, Clone: B27, Cat#: 506510, Lot# B237406, Dil: 1:200)  
 Anti-human-TNF- $\alpha$ , BV510 (Biolegend, Clone: Mab11, Cat#: 502949, Lot# B339729, Dil: 1:200)  
 Anti-human-IL-21, PE (Biolegend, Clone: 3A3-N2, Cat#: 513004, Lot# B335103, Dil: 1:100)  
 Anti-human-CD4, BV605 (Biolegend, Clone: RPA-T4, Cat#: 300556, Lot# B289706, Dil: 1:200)  
 Anti-human-CD19, PE-Cy7 (Biolegend, Clone: HIB19, Cat#: 302216, Lot# B172415, Dil: 1:200)  
 Anti-human-CD25, FITC (Biolegend, Clone: BC96, Cat#: 302604, Lot# B339583, Dil: 1:100)  
 Anti-human-T-bet, PE-Cy7 (Biolegend, Clone: 4B10, Cat#: 644824, Lot# B331455, Dil: 1:100)  
 Anti-human-FcRL4, PE (Biolegend, Clone: 413D12, Cat#: 340203, Lot# B248797, Dil: 1:50)  
 Anti-human-FcRL5, APC (Biolegend, Clone: 509f6, Cat#: 340305, Lot# B309350, Dil: 1:50)  
 Anti-human-CD85j, APC (Biolegend, Clone: GHI/75, Cat#: 333719, Lot# B279700, Dil: 1:50)  
 Anti-human-CXCR3, Alexa-Fluor-700 (Biolegend, Clone: G025H7, Cat#: 353741, Lot# B271260, Dil: 1:100)  
 Anti-human-CD95, Alexa-Fluor-700 (Biolegend, Clone: DX2, Cat#: 305647, Lot# B275145, Dil: 1:00)  
 Anti-human-BAFF-R, PE-Cy7 (Biolegend, Clone: 11C1, Cat#: 316919, Lot# B294228, Dil: 1:125)  
 Anti-human-IgL, FITC (Biolegend, Clone: MHL-38, Cat#: 316606, Lot# B207106, Dil: 1:200)  
 Anti-human-IgK, Pacific Blue (Biolegend, Clone: MHK-49, Cat#: 316524, Lot# B160046, Dil: 1:200)

#### Confocal Microscopy:

Anti-human-CD4, Alexa-Fluor-488 (Abcam, Clone: EPR6855, Cat#: ab196372, Dil: 1:100)  
 Anti-human-CD19, Alexa-Fluor-555 (Abcam, Clone: EPR5906, Cat#: ab274888, Dil: 1:100)  
 Anti-human-T-bet, Alexa-Fluor-647 (Abcam, Clone: EPR9301, Cat#: ab225198, Dil: 1:100)  
 Anti-human-PD-1, Alexa-Fluor-647 (Abcam, Clone: EPR4877(2), Cat#: ab201825, Dil: 1:100)

#### B cell enrichment:

Anti-human CD20 magnetic beads (Miltenyi Biotec, Cat# 130-091-104)

#### ELISA:

9G4 Human - Purified rat anti-idiotypic antibody to VH4-34 gene-encoded (IgM Biosciences, Dil: 1:500)  
 Goat-anti-Human IgM Secondary Antibody, HRP, (Thermo Fisher Scientific, Cat# 31415, Lot#: OL1793879, Dil: 1:4000)  
 Goat-anti-Human IgG F(ab')<sub>2</sub> Secondary Antibody, HRP, (Thermo Fisher Scientific, Cat# 31414, Lot#: TH2622475, Dil: 1:5000)

#### Immunohistochemistry:

Anti-human-CD21 (Cell Marque Tissue Diagnostics, 2G9 Mouse Monoclonal, Cat# 760-4245, conc. 0.5  $\mu$ g/mL)  
 Anti-human-CD20 (Roche Diagnostics, L26 Mouse Monoclonal, Cat# 760-2531, conc. 0.3  $\mu$ g/mL)  
 Anti-human-BCL-2 (Roche Diagnostics, I24 Mouse Monoclonal, Cat# 790-4464, conc. 2.62  $\mu$ g/mL)  
 Anti-human-CD4 (Roche Diagnostics, SP35 Rabbit Monoclonal, Cat# 790-4423, conc. 2.5  $\mu$ g/mL)

#### Validation

In the study we only used commercially available antibodies validated by the manufacturer. All antibody validation is provided on supplier website. In case of flow cytometry, optimal dilution for each antibody used was determined by single staining of the target lymphocytes (human B or T cells) with serial dilution of the given antibody. Optimal dilutions for HRP-conjugated secondary antibodies were determined experimentally with ELISA.

## Eukaryotic cell lines

### Policy information about [cell lines](#)

Cell line source(s)	HEK293T cell line was purchased (ATCC, #CRL-3216) and kindly provided by Dr. Donna Eason (University of South Florida).
Authentication	HEK293T cell line was authenticated prior to receipt by the commercial vendor.
Mycoplasma contamination	HEK293T cell line was not tested for mycoplasma.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were used.

## Palaeontology and Archaeology

Specimen provenance	<i>Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information). Permits should encompass collection and, where applicable, export.</i>
Specimen deposition	<i>Indicate where the specimens have been deposited to permit free access by other researchers.</i>
Dating methods	<i>If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.</i>

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

**Ethics oversight**

*Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.*

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

**Laboratory animals**

*For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.*

**Wild animals**

*Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.*

**Field-collected samples**

*For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.*

**Ethics oversight**

*Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.*

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Policy information about [studies involving human research participants](#)

**Population characteristics**

Population characteristics are detailed in Supplementary Table 1, RAG1/2 variants are detailed in Supplementary Table 2.

**Recruitment**

16 patients carrying pathogenic or likely pathogenic hypomorphic RAG1 or 2 gene variants were recruited to our study. All except an asymptomatic infant (P1), displayed clinical phenotype of combined immune deficiency with granuloma/ autoimmunity phenotype according to the enrollment criteria described in the Methods. Peripheral blood sample was available from 15 patients; spleen histology sections were available from one patient. No self-selection bias occurred. A patient was enrolled to the study after referral from collaborating physicians, if met the enrollment criteria. 27 healthy subjects representing age groups corresponding to patient samples were enrolled in the study according to the enrollment criteria described in the Methods.

**Ethics oversight**

The study was approved by the local ethics committee of the University of South Florida (USF-Pro00035468, USF-Pro00025693) and Johns Hopkins Medical Institute / Johns Hopkins All Children's Hospital (JHMI-IRB00175372, JHMI-IRB00097062, JHMI-IRB00097938). All protocols followed local ethics recommendations and informed, written consent was obtained from all participants, parents or legally authorized representative.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

**Clinical trial registration**

*Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.*

**Study protocol**

*Note where the full trial protocol can be accessed OR if not available, explain why.*

**Data collection**

*Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.*

**Outcomes**

*Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.*

## Dual use research of concern

Policy information about [dual use research of concern](#)

**Hazards**

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

- | No                       | Yes   |
|--------------------------|---|
| <input type="checkbox"/> | <input type="checkbox"/> Public health              |
| <input type="checkbox"/> | <input type="checkbox"/> National security          |
| <input type="checkbox"/> | <input type="checkbox"/> Crops and/or livestock     |
| <input type="checkbox"/> | <input type="checkbox"/> Ecosystems                 |
| <input type="checkbox"/> | <input type="checkbox"/> Any other significant area |

## Experiments of concern

Does the work involve any of these experiments of concern:

- | No                       | Yes  |
|--------------------------|--|
| <input type="checkbox"/> | <input type="checkbox"/> Demonstrate how to render a vaccine ineffective                             |
| <input type="checkbox"/> | <input type="checkbox"/> Confer resistance to therapeutically useful antibiotics or antiviral agents |
| <input type="checkbox"/> | <input type="checkbox"/> Enhance the virulence of a pathogen or render a nonpathogen virulent        |
| <input type="checkbox"/> | <input type="checkbox"/> Increase transmissibility of a pathogen                                     |
| <input type="checkbox"/> | <input type="checkbox"/> Alter the host range of a pathogen  |
| <input type="checkbox"/> | <input type="checkbox"/> Enable evasion of diagnostic/detection modalities                           |
| <input type="checkbox"/> | <input type="checkbox"/> Enable the weaponization of a biological agent or toxin                     |
| <input type="checkbox"/> | <input type="checkbox"/> Any other potentially harmful combination of experiments and agents         |

## ChIP-seq

### Data deposition

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

#### Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

#### Files in database submission

Provide a list of all files available in the database submission.

#### Genome browser session (e.g. [UCSC](#))

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

## Methodology

### Replicates

Describe the experimental replicates, specifying number, type and replicate agreement.

### Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

### Antibodies

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.

### Peak calling parameters

Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.

### Data quality

Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

### Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.



## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation	Sample preparation is described in the Methods section.
Instrument	FACSAria II (BD Biosciences)
Software	FACSDiva software version 10 was used for data acquisition. The analysis of flow cytometry data was performed using FlowJo software (version 10.7.1) and plugins FlowSOM (v2.5), tSNE (v2.0), Hyperfinder (v0.6.2) and DownSample (v3.0) FlowJo.
Cell population abundance	Bulk cell sorts were performed using 4-Way Purity precision mode. For BCR repertoire sequencing, 25-50K specific B cells were sorted from each subject and used for RNA isolation. For in vitro B cell activation and B cell – Tfh cell co-culture assays, 100K-200K B and Tfh cells were sorted from each subject and cultured as described in the Methods. Purity of post-sort fractions were determined by flow cytometry ensuring a purity of >95% defined as the ratio of target cells and total cells. Single cell sorts were performed using Single Cell precision mode.
Gating strategy	In all experiments human peripheral blood-derived B or T lymphocytes or in vitro cultured B lymphocytes were used. Pre-gating was performed on single cells using FSC-A/FSC-H, then on lymphocytes using FSC-H/SSC-H, followed by cell debris and dead cell exclusion using fixable viability dye eFluor-780 (ThermoFisher Scientific). Total B cells were defined by the mean of CD19 expression, CD4 helper T cells were defined by the mean of CD4 expression. For specific B and T subset identification, individual gating strategies are described in the related Methods sections and the figure legends for each experiment. The detailed gating strategy for the sixteen B cell subsets defined in the manuscript is shown in Supplementary Figure 3.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type	Indicate task or resting state; event-related or block design.
Design specifications	Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.
Behavioral performance measures	State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

### Acquisition

Imaging type(s)	Specify: functional, structural, diffusion, perfusion.
Field strength	Specify in Tesla
Sequence & imaging parameters	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.
Diffusion MRI	<input type="checkbox"/> Used <input type="checkbox"/> Not used

### Preprocessing

Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

Normalization template	<i>Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.</i>
Noise and artifact removal	<i>Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).</i>
Volume censoring	<i>Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.</i>

## Statistical modeling & inference

Model type and settings	<i>Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).</i>
Effect(s) tested	<i>Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.</i>
Specify type of analysis:	<input type="checkbox"/> Whole brain <input type="checkbox"/> ROI-based <input type="checkbox"/> Both
Statistic type for inference (See <a href="#">Eklund et al. 2016</a> )	<i>Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.</i>
Correction	<i>Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).</i>

## Models & analysis

n/a	Involvement in the study
<input type="checkbox"/>	<input type="checkbox"/> Functional and/or effective connectivity
<input type="checkbox"/>	<input type="checkbox"/> Graph analysis
<input type="checkbox"/>	<input type="checkbox"/> Multivariate modeling or predictive analysis
Functional and/or effective connectivity	<i>Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).</i>
Graph analysis	<i>Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).</i>
Multivariate modeling and predictive analysis	<i>Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.</i>